<?xml version="1.0" encoding="UTF-8"?><?xml-stylesheet href="https://www.accessdata.fda.gov/spl/stylesheet/spl.xsl" type="text/xsl"?>
<document xmlns="urn:hl7-org:v3" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="urn:hl7-org:v3 https://www.accessdata.fda.gov/spl/schema/spl.xsd">
   <id root="3b0b0981-a681-4c0c-91fb-b662277e92ad"/>
   <code code="34391-3" codeSystem="2.16.840.1.113883.6.1" displayName="HUMAN PRESCRIPTION DRUG LABEL"/>
   <title>These highlights do not include all the information needed to use ATZUMI safely and effectively. See full prescribing information for ATZUMI. <br/>
      <br/> ATZUMI™ (dihydroergotamine) nasal powder <br/> Initial U.S. Approval:  1946</title>
   <effectiveTime value="20250508"/>
   <setId root="0982a44a-dc0c-75c0-e063-6394a90a6d6c"/>
   <versionNumber value="2"/>
   <author>
      <time/>
      <assignedEntity>
         <representedOrganization>
            <id extension="117333645" root="1.3.6.1.4.1.519.1"/>
            <name>Satsuma Pharmaceuticals, Inc.</name>
            <assignedEntity>
               <assignedOrganization/>
            </assignedEntity>
         </representedOrganization>
      </assignedEntity>
   </author>
   <component>
      <structuredBody>
         <component>
            <section ID="DLDE">
               <id root="de9b3c38-9459-48b0-9ebc-4f93ca0efcb3"/>
               <code code="48780-1" codeSystem="2.16.840.1.113883.6.1" displayName="SPL PRODUCT DATA ELEMENTS SECTION"/>
               <effectiveTime value="20250401"/>
               <subject>
                  <manufacturedProduct>
                     <manufacturedProduct>
                        <code code="76978-101" codeSystem="2.16.840.1.113883.6.69"/>
                        <name>ATZUMI</name>
                        <formCode code="C42972" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="POWDER"/>
                        <asEntityWithGeneric>
                           <genericMedicine>
                              <name>DIHYDROERGOTAMINE MESYLATE</name>
                           </genericMedicine>
                        </asEntityWithGeneric>
                        <ingredient classCode="ACTIB">
                           <quantity>
                              <numerator value="5.2" unit="mg"/>
                              <denominator value="1" unit="1"/>
                           </quantity>
                           <ingredientSubstance>
                              <code code="81AXN7R2QT" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>DIHYDROERGOTAMINE MESYLATE</name>
                              <activeMoiety>
                                 <activeMoiety>
                                    <code code="436O5HM03C" codeSystem="2.16.840.1.113883.4.9"/>
                                    <name>DIHYDROERGOTAMINE</name>
                                 </activeMoiety>
                              </activeMoiety>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="OP1R32D61U" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>MICROCRYSTALLINE CELLULOSE</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="3NXW29V3WO" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>HYPROMELLOSE, UNSPECIFIED</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="3OWL53L36A" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>MANNITOL</name>
                           </ingredientSubstance>
                        </ingredient>
                        <asContent>
                           <quantity>
                              <numerator value="1" unit="1"/>
                              <denominator value="1"/>
                           </quantity>
                           <containerPackagedProduct>
                              <formCode code="C43176" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="BOTTLE, UNIT-DOSE"/>
                              <asContent>
                                 <quantity>
                                    <numerator value="1" unit="1"/>
                                    <denominator value="1"/>
                                 </quantity>
                                 <containerPackagedProduct>
                                    <code code="76978-101-11" codeSystem="2.16.840.1.113883.6.69"/>
                                    <formCode code="C43182" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="CARTON"/>
                                 </containerPackagedProduct>
                                 <subjectOf>
                                    <marketingAct>
                                       <code code="C53292" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                                       <statusCode code="active"/>
                                       <effectiveTime>
                                          <low value="20250430"/>
                                       </effectiveTime>
                                    </marketingAct>
                                 </subjectOf>
                              </asContent>
                           </containerPackagedProduct>
                           <subjectOf>
                              <characteristic>
                                 <code code="SPLCMBPRDTP" codeSystem="2.16.840.1.113883.1.11.19255"/>
                                 <value code="C102835" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="Type 2: Prefilled Drug Delivery Device/System (syringe, patch, etc.)" xsi:type="CV"/>
                              </characteristic>
                           </subjectOf>
                        </asContent>
                        <asContent>
                           <quantity>
                              <numerator value="1" unit="1"/>
                              <denominator value="1"/>
                           </quantity>
                           <containerPackagedProduct>
                              <formCode code="C43176" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="BOTTLE, UNIT-DOSE"/>
                              <asContent>
                                 <quantity>
                                    <numerator value="8" unit="1"/>
                                    <denominator value="1"/>
                                 </quantity>
                                 <containerPackagedProduct>
                                    <code code="76978-101-08" codeSystem="2.16.840.1.113883.6.69"/>
                                    <formCode code="C43182" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="CARTON"/>
                                 </containerPackagedProduct>
                                 <subjectOf>
                                    <marketingAct>
                                       <code code="C53292" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                                       <statusCode code="active"/>
                                       <effectiveTime>
                                          <low value="20250430"/>
                                       </effectiveTime>
                                    </marketingAct>
                                 </subjectOf>
                              </asContent>
                           </containerPackagedProduct>
                           <subjectOf>
                              <characteristic>
                                 <code code="SPLCMBPRDTP" codeSystem="2.16.840.1.113883.1.11.19255"/>
                                 <value code="C102835" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="Type 2: Prefilled Drug Delivery Device/System (syringe, patch, etc.)" xsi:type="CV"/>
                              </characteristic>
                           </subjectOf>
                        </asContent>
                     </manufacturedProduct>
                     <subjectOf>
                        <approval>
                           <id extension="NDA217901" root="2.16.840.1.113883.3.150"/>
                           <code code="C73594" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="NDA"/>
                           <author>
                              <territorialAuthority>
                                 <territory>
                                    <code code="USA" codeSystem="2.16.840.1.113883.5.28"/>
                                 </territory>
                              </territorialAuthority>
                           </author>
                        </approval>
                     </subjectOf>
                     <subjectOf>
                        <marketingAct>
                           <code code="C53292" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                           <statusCode code="active"/>
                           <effectiveTime>
                              <low value="20250430"/>
                           </effectiveTime>
                        </marketingAct>
                     </subjectOf>
                     <consumedIn>
                        <substanceAdministration>
                           <routeCode code="C38284" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="NASAL"/>
                        </substanceAdministration>
                     </consumedIn>
                  </manufacturedProduct>
               </subject>
            </section>
         </component>
         <component>
            <section ID="BOX">
               <id root="d44aba09-69b7-433c-a38e-3abd06e866e4"/>
               <code code="34066-1" codeSystem="2.16.840.1.113883.6.1" displayName="BOXED WARNING SECTION"/>
               <title>
                  <content styleCode="emphasis">WARNING: PERIPHERAL ISCHEMIA FOLLOWING COADMINISTRATION WITH STRONG CYP3A4 INHIBITORS</content>
               </title>
               <text>
                  <paragraph styleCode="bold">Serious and/or life-threatening peripheral ischemia has been associated with the coadministration of dihydroergotamine with strong CYP3A4 inhibitors. Because CYP3A4 inhibition elevates the serum levels of dihydroergotamine, the risk for vasospasm leading to cerebral ischemia and/or ischemia of the extremities is increased. Hence, concomitant use of ATZUMI with strong CYP3A4 inhibitors is contraindicated <content styleCode="italics">[see <linkHtml href="#S4">Contraindications (4)</linkHtml>, <linkHtml href="#S5.1">Warnings and Precautions (5.1)</linkHtml>, and <linkHtml href="#S7.1">Drug Interactions (7.1)</linkHtml>].</content>
                  </paragraph>
               </text>
               <effectiveTime value="20250401"/>
               <excerpt>
                  <highlight>
                     <text>
                        <paragraph>WARNING: PERIPHERAL ISCHEMIA FOLLOWING COADMINISTRATION WITH STRONG CYP3A4 INHIBITORS</paragraph>
                        <paragraph>
                           <content styleCode="italics">See full prescribing information for complete boxed warning.</content>
                        </paragraph>
                        <paragraph styleCode="bold">Serious and/or life-threatening peripheral ischemia has been associated with the coadministration of dihydroergotamine with strong CYP3A4 inhibitors. Because CYP3A4 inhibition elevates the serum levels of dihydroergotamine, the risk for vasospasm leading to cerebral ischemia and/or ischemia of the extremities is increased. Hence, concomitant use of ATZUMI with strong CYP3A4 inhibitors is contraindicated. (<linkHtml href="#S4">4</linkHtml>, <linkHtml href="#S5.1">5.1</linkHtml>, <linkHtml href="#S7.1">7.1</linkHtml>)</paragraph>
                     </text>
                  </highlight>
               </excerpt>
            </section>
         </component>
         <component>
            <section ID="S1">
               <id root="ea01adff-4312-4951-8519-8dbbcfdce23f"/>
               <code code="34067-9" codeSystem="2.16.840.1.113883.6.1" displayName="INDICATIONS &amp; USAGE SECTION"/>
               <title>1 INDICATIONS AND USAGE</title>
               <text>
                  <paragraph>ATZUMI is indicated for the acute treatment of migraine with or without aura in adults.</paragraph>
               </text>
               <effectiveTime value="20250401"/>
               <excerpt>
                  <highlight>
                     <text>
                        <paragraph>ATZUMI is an ergotamine derivative indicated for the acute treatment of migraine with or without aura in adults. (<linkHtml href="#S1">1</linkHtml>)</paragraph>
                        <paragraph>
                           <content styleCode="underline">Limitations of Use</content>
                        </paragraph>
                        <paragraph>ATZUMI is not indicated for the preventive treatment of migraine or for the management of hemiplegic migraine or migraine with brainstem aura. (<linkHtml href="#S1">1</linkHtml>)</paragraph>
                     </text>
                  </highlight>
               </excerpt>
               <component>
                  <section>
                     <id root="db4e8acb-dc92-424e-b516-3f2aef91e426"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <text>
                        <paragraph>
                           <content styleCode="underline">Limitations of Use</content>
                        </paragraph>
                        <paragraph>ATZUMI is not indicated for the preventive treatment of migraine.</paragraph>
                        <paragraph>ATZUMI is not indicated for the management of hemiplegic migraine or migraine with brainstem aura.</paragraph>
                     </text>
                     <effectiveTime value="20250401"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="S2">
               <id root="9dbaa9e3-456e-4506-8acc-2c397705bace"/>
               <code code="34068-7" codeSystem="2.16.840.1.113883.6.1" displayName="DOSAGE &amp; ADMINISTRATION SECTION"/>
               <title>2 DOSAGE AND ADMINISTRATION</title>
               <effectiveTime value="20250401"/>
               <excerpt>
                  <highlight>
                     <text>
                        <list listType="unordered" styleCode="disc">
                           <item>ATZUMI is for nasal administration only. (<linkHtml href="#S2.1">2.1</linkHtml>)</item>
                           <item>The recommended dose of ATZUMI is 5.2 mg, the contents of one nasal device, administered into one nostril. (<linkHtml href="#S2.1">2.1</linkHtml>)</item>
                           <item>To administer a dose, the white air pump of the ATZUMI device must be squeezed three separate times into one nostril. (<linkHtml href="#S2.1">2.1</linkHtml>)</item>
                           <item>The dose may be repeated, if needed, a minimum of 1 hour after the first dose. The maximum dose in a 24-hour period is 10.4 mg (two doses of ATZUMI 5.2 mg). (<linkHtml href="#S2.1">2.1</linkHtml>)</item>
                           <item>The safety of taking more than 4 doses within a 7-day period or 12 doses within a 30-day period has not been established. (<linkHtml href="#S2.1">2.1</linkHtml>)</item>
                           <item>Prior to initiation, a cardiovascular evaluation is recommended. (<linkHtml href="#S2.2">2.2</linkHtml>)</item>
                        </list>
                     </text>
                  </highlight>
               </excerpt>
               <component>
                  <section ID="S2.1">
                     <id root="65ebac73-0233-4dff-af42-f17d2f2fcd21"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>2.1  Dosing Information</title>
                     <text>
                        <paragraph>ATZUMI is for nasal administration only.</paragraph>
                        <paragraph>The recommended dose of ATZUMI is 5.2 mg (the contents of one nasal device) and is administered as a powdered medicine into one nostril <content styleCode="italics">[see <linkHtml href="#S2.3">Dosage and Administration (2.3)</linkHtml>].</content>
                        </paragraph>
                        <paragraph>The dose may be repeated, if needed, a minimum of 1 hour after the first dose. The maximum dose in a 24-hour period is 10.4 mg (two doses of ATZUMI 5.2 mg). The safety of taking more than 4 doses in a 7-day period or 12 doses within a 30-day period has not been established.</paragraph>
                     </text>
                     <effectiveTime value="20250401"/>
                  </section>
               </component>
               <component>
                  <section ID="S2.2">
                     <id root="090b0ddf-ae34-4913-9888-dd35e1af7c30"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>2.2  Assessment Prior to First Dose</title>
                     <text>
                        <paragraph>Prior to initiation of ATZUMI, a cardiovascular evaluation is recommended <content styleCode="italics">[see <linkHtml href="#S5.2">Warnings and Precautions (5.2)</linkHtml>]</content>. For patients with risk factors predictive of coronary artery disease who are determined to have a satisfactory cardiovascular evaluation, it is strongly recommended that administration of the first dose of ATZUMI take place in the setting of an equipped healthcare facility.</paragraph>
                     </text>
                     <effectiveTime value="20250401"/>
                  </section>
               </component>
               <component>
                  <section ID="S2.3">
                     <id root="959108cd-dd71-449e-acb0-9cce30bce525"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>2.3   Administration Instructions</title>
                     <text>
                        <list listType="unordered" styleCode="disc">
                           <item>Priming is not required.</item>
                           <item>To administer a dose of ATZUMI, remove the round blue tab from the blue nozzle, and insert the blue nozzle into one nostril.  Squeeze the white air pump 3 separate times into 1 nostril while inhaling.  Allow the white air pump to expand back to its original shape between squeezes <content styleCode="italics">[see <linkHtml href="#IFU">Instructions for Use</linkHtml>].</content>
                           </item>
                           <item>Fast, complete, pulse-like squeezes are needed to deliver the complete dose. Do not squeeze slowly, partially or with any hesitation.</item>
                        </list>
                     </text>
                     <effectiveTime value="20250401"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="S3">
               <id root="3643d094-083f-4ab2-9e49-9f98df72c4dc"/>
               <code code="43678-2" codeSystem="2.16.840.1.113883.6.1" displayName="DOSAGE FORMS &amp; STRENGTHS SECTION"/>
               <title>3 DOSAGE FORMS AND STRENGTHS</title>
               <text>
                  <paragraph>Nasal Powder: 5.2 mg dihydroergotamine as a white powder in a single-dose nasal device.</paragraph>
               </text>
               <effectiveTime value="20250401"/>
               <excerpt>
                  <highlight>
                     <text>
                        <paragraph>Nasal powder: 5.2 mg (<linkHtml href="#S3">3</linkHtml>)</paragraph>
                     </text>
                  </highlight>
               </excerpt>
            </section>
         </component>
         <component>
            <section ID="S4">
               <id root="0391cb09-2bd7-4976-97a4-e5dcb7adff15"/>
               <code code="34070-3" codeSystem="2.16.840.1.113883.6.1" displayName="CONTRAINDICATIONS SECTION"/>
               <title>4 CONTRAINDICATIONS</title>
               <text>
                  <paragraph>ATZUMI is contraindicated in patients:</paragraph>
                  <list listType="unordered" styleCode="disc">
                     <item>with concomitant use of strong CYP3A4 inhibitors <content styleCode="italics">[see <linkHtml href="#S5.1">Warnings and Precautions (5.1)</linkHtml> and <linkHtml href="#S7.1">Drug Interactions (7.1)</linkHtml>]</content>
                     </item>
                     <item>with ischemic heart disease (e.g., angina pectoris, history of myocardial infarction, or documented silent ischemia) or patients who have clinical symptoms or findings consistent with coronary artery vasospasm, including Prinzmetal's variant angina <content styleCode="italics">[see <linkHtml href="#S5.4">Warnings and Precautions (5.4)</linkHtml>]</content>
                     </item>
                     <item>with uncontrolled hypertension <content styleCode="italics">[see <linkHtml href="#S5.5">Warnings and Precautions (5.5)</linkHtml>]</content>
                     </item>
                     <item>with peripheral arterial disease</item>
                     <item>with sepsis</item>
                     <item>following vascular surgery</item>
                     <item>with severe hepatic impairment</item>
                     <item>with severe renal impairment</item>
                     <item>with known hypersensitivity to ergot alkaloids</item>
                     <item>with recent use (i.e., within 24 hours) of other 5-HT<sub>1</sub> agonists or ergotamine-containing or ergot-type medications <content styleCode="italics">[see <linkHtml href="#S7.2">Drug Interactions (7.2)</linkHtml>]</content>
                     </item>
                     <item>with concomitant use of peripheral and central vasoconstrictors because the combination may result in additive or synergistic elevation of blood pressure <content styleCode="italics">[see <linkHtml href="#S5.5">Warnings and Precautions (5.5)</linkHtml>]</content>
                     </item>
                  </list>
               </text>
               <effectiveTime value="20250401"/>
               <excerpt>
                  <highlight>
                     <text>
                        <list listType="unordered" styleCode="disc">
                           <item>Concomitant use of strong CYP3A4 inhibitors. (<linkHtml href="#S4">4</linkHtml>)</item>
                           <item>Ischemic heart disease or coronary artery vasospasm (<linkHtml href="#S4">4</linkHtml>)</item>
                           <item>Uncontrolled hypertension, peripheral arterial diseases, sepsis, following vascular surgery, or severe hepatic or renal impairment (<linkHtml href="#S4">4</linkHtml>)</item>
                           <item>Hypersensitivity to ergot alkaloids (<linkHtml href="#S4">4</linkHtml>)</item>
                           <item>Concomitant use of other 5-HT<sub>1</sub> agonists or ergotamine-containing or ergot-type medications within 24 hours (<linkHtml href="#S4">4</linkHtml>)</item>
                           <item>Concomitant use of peripheral and central vasoconstrictors (<linkHtml href="#S4">4</linkHtml>)</item>
                        </list>
                     </text>
                  </highlight>
               </excerpt>
            </section>
         </component>
         <component>
            <section ID="S5">
               <id root="0f9a9614-32a7-4603-80bc-96e665f031bf"/>
               <code code="43685-7" codeSystem="2.16.840.1.113883.6.1" displayName="WARNINGS AND PRECAUTIONS SECTION"/>
               <title>5 WARNINGS AND PRECAUTIONS</title>
               <effectiveTime value="20250401"/>
               <excerpt>
                  <highlight>
                     <text>
                        <list listType="unordered" styleCode="disc">
                           <item>Myocardial Ischemia and/or Infarction, Other Cardiac Adverse Reactions, and Fatalities: In patients with risk factors predictive of coronary artery disease, consider first dose administration under medical supervision with electrocardiogram. (<linkHtml href="#S5.2">5.2</linkHtml>)</item>
                           <item>Cerebrovascular Adverse Reactions and Fatalities: Cerebral hemorrhage, subarachnoid hemorrhage, and stroke have been reported; discontinue ATZUMI if suspected. (<linkHtml href="#S5.3">5.3</linkHtml>)</item>
                           <item>Other Vasospasm Related Adverse Reactions: ATZUMI may cause vasospasm or elevation in blood pressure. Discontinue if signs or symptoms of vasoconstriction develop. (<linkHtml href="#S5.4">5.4</linkHtml>, <linkHtml href="#S5.5">5.5</linkHtml>) </item>
                           <item>Medication Overuse Headache: Detoxification may be necessary. (<linkHtml href="#S5.6">5.6</linkHtml>)</item>
                           <item>Preterm Labor: Advise pregnant women of the risk. (<linkHtml href="#S5.7">5.7</linkHtml>, <linkHtml href="#S8.1">8.1</linkHtml>)</item>
                           <item>Fibrotic Complications: Pleural and retroperitoneal fibrosis have been reported following prolonged daily use of dihydroergotamine. Administration of ATZUMI should not exceed the dosing guidelines or be used for chronic daily administration. (<linkHtml href="#S5.8">5.8</linkHtml>)</item>
                           <item>Local Irritation: If severe local irritation occurs for no other attributable reason, suspend ATZUMI until resolution. (<linkHtml href="#S5.9">5.9</linkHtml>)</item>
                        </list>
                     </text>
                  </highlight>
               </excerpt>
               <component>
                  <section ID="S5.1">
                     <id root="972df40a-a2ae-4dba-8d90-e852ec7594d0"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>5.1   Peripheral Ischemia Following Coadministration with Strong CYP3A4 Inhibitors</title>
                     <text>
                        <paragraph>Serious and/or life-threatening peripheral ischemia has been associated with the coadministration of dihydroergotamine with strong CYP3A4 inhibitors, including protease inhibitors, macrolide antibiotics, and antifungals. Because CYP3A4 inhibition elevates the serum levels of dihydroergotamine, the risk for vasospasm leading to cerebral ischemia and/or ischemia of the extremities is increased. Hence, concomitant use of ATZUMI with strong CYP3A4 inhibitors is contraindicated <content styleCode="italics">[see <linkHtml href="#S4">Contraindications (4)</linkHtml> and <linkHtml href="#S7.1">Drug Interactions (7.1)</linkHtml>]</content>.</paragraph>
                     </text>
                     <effectiveTime value="20250401"/>
                  </section>
               </component>
               <component>
                  <section ID="S5.2">
                     <id root="00473a27-bc21-4b29-a85f-026568190345"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>5.2  Myocardial Ischemia and/or Infarction, Other Cardiac Adverse Reactions, and Fatalities</title>
                     <text>
                        <paragraph>The potential for cardiac adverse reactions exists with ATZUMI treatment. Serious adverse cardiac events, including some that have been fatal, have occurred following use of dihydroergotamine. These events have included acute myocardial infarction, life-threatening disturbances of cardiac rhythm (e.g., ventricular tachycardia and ventricular fibrillation), coronary artery vasospasm, and transient myocardial ischemia.</paragraph>
                        <paragraph>Prior to initiation of ATZUMI, a cardiovascular evaluation is recommended to determine if the patient is free of coronary artery and ischemic myocardial disease or other significant underlying cardiovascular disease. If, during the cardiovascular evaluation, the patient's medical history (including risk factors), or electrocardiographic investigation, findings are consistent with coronary artery vasospasm or myocardial ischemia, ATZUMI should not be administered <content styleCode="italics">[see <linkHtml href="#S4">Contraindications (4)</linkHtml>]</content>.</paragraph>
                        <paragraph>For patients with risk factors predictive of coronary artery disease (e.g., hypertension, hypercholesterolemia, smoker, obesity, diabetes, strong family history of coronary artery disease, females who are surgically or physiologically postmenopausal, or males who are over 40 years of age) who are determined to have a satisfactory cardiovascular evaluation, it is strongly recommended that administration of the first dose of ATZUMI take place in the setting of an equipped healthcare facility, unless the patient has previously received dihydroergotamine. During the interval immediately following the first use of ATZUMI, an electrocardiogram is recommended in those patients with risk factors because ischemia can occur in the absence of clinical symptoms. </paragraph>
                     </text>
                     <effectiveTime value="20250401"/>
                  </section>
               </component>
               <component>
                  <section ID="S5.3">
                     <id root="4c87caf4-b0f1-4a88-af27-3fddf6d103c2"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>5.3  Cerebrovascular Adverse Reactions and Fatalities</title>
                     <text>
                        <paragraph>The potential for adverse cerebrovascular adverse reactions exists with ATZUMI treatment. Cerebral hemorrhage, subarachnoid hemorrhage, stroke, and other cerebrovascular events have been reported in patients treated with dihydroergotamine; and some have resulted in fatalities.  In a number of cases, it appears possible that the cerebrovascular events were primary, the dihydroergotamine having been administered in the incorrect belief that the symptoms experienced were a consequence of migraine, when they were not. It should be noted that patients with migraine may be at increased risk of certain cerebrovascular events (e.g., stroke, hemorrhage, transient ischemic attack).</paragraph>
                        <paragraph>Discontinue ATZUMI if a cerebrovascular event is suspected.</paragraph>
                     </text>
                     <effectiveTime value="20250401"/>
                  </section>
               </component>
               <component>
                  <section ID="S5.4">
                     <id root="ea6d731f-682d-4d1d-83e7-f8a361a54b8a"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>5.4  Other Vasospasm Related Adverse Reactions</title>
                     <text>
                        <paragraph>ATZUMI, like other ergot alkaloids, may cause vasospastic reactions other than coronary artery vasospasm. Myocardial, peripheral vascular, and colonic ischemia have been reported with dihydroergotamine.</paragraph>
                        <paragraph>Dihydroergotamine associated vasospastic phenomena may also cause muscle pains, numbness, coldness, pallor, and cyanosis of the digits. In patients with compromised circulation, persistent vasospasm may result in gangrene or death. ATZUMI should be discontinued immediately if signs or symptoms of vasoconstriction develop.</paragraph>
                        <paragraph>Patients who experience other symptoms or signs suggestive of decreased arterial flow, such as ischemic bowel syndrome or Raynaud's syndrome, following the use of any 5-HT<sub>1</sub> agonist, including ATZUMI, should be evaluated by a healthcare provider.</paragraph>
                     </text>
                     <effectiveTime value="20250401"/>
                  </section>
               </component>
               <component>
                  <section ID="S5.5">
                     <id root="07d1df7c-aa77-46f2-8418-5e96a63de0e9"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>5.5 Increase in Blood Pressure</title>
                     <text>
                        <paragraph>Significant elevation in blood pressure has been reported on rare occasions in patients with and without a history of hypertension treated with dihydroergotamine. ATZUMI is contraindicated in patients with uncontrolled hypertension <content styleCode="italics">[see <linkHtml href="#S4">Contraindications (4)</linkHtml>].</content>
                        </paragraph>
                        <paragraph>An 18% increase in mean pulmonary artery pressure was seen following dosing with another 5-HT<sub>1</sub> agonist in a study evaluating subjects undergoing cardiac catheterization.</paragraph>
                     </text>
                     <effectiveTime value="20250401"/>
                  </section>
               </component>
               <component>
                  <section ID="S5.6">
                     <id root="5eaaab0a-b1a7-4604-9080-50ec6735cc2a"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>5.6 Medication Overuse Headache</title>
                     <text>
                        <paragraph>Overuse of acute migraine drugs (e.g., ergotamines, triptans, opioids, or a combination of these drugs for 10 or more days per month) may lead to exacerbation of headache (i.e., medication overuse headache). Medication overuse headache may present as migraine-like daily headaches or as a marked increase in frequency of migraine attacks. Detoxification of patients including withdrawal of the overused drugs and treatment of withdrawal symptoms (which often includes a transient worsening of headache) may be necessary.</paragraph>
                     </text>
                     <effectiveTime value="20250401"/>
                  </section>
               </component>
               <component>
                  <section ID="S5.7">
                     <id root="71d7ffff-dbb4-4052-8b52-f94f629ece4e"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>5.7 Preterm Labor</title>
                     <text>
                        <paragraph>Based on the mechanism of action of dihydroergotamine and findings from the published literature, ATZUMI may cause preterm labor. Avoid use of ATZUMI during pregnancy <content styleCode="italics">[see <linkHtml href="#S8.1">Use in Specific Populations (8.1)</linkHtml> and <linkHtml href="#S12.2">Clinical Pharmacology (12.2)</linkHtml>]</content>.</paragraph>
                     </text>
                     <effectiveTime value="20250401"/>
                  </section>
               </component>
               <component>
                  <section ID="S5.8">
                     <id root="f33f6a2f-b318-47a4-99e5-47a86778f7ed"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>5.8  Fibrotic Complications</title>
                     <text>
                        <paragraph>The potential for fibrotic complications exists with ATZUMI treatment. There have been reports of pleural and retroperitoneal fibrosis in patients following prolonged daily use of dihydroergotamine . Rarely, prolonged daily use of other ergot alkaloid drugs has been associated with cardiac valvular fibrosis. Rare cases have also been reported in association with the use of dihydroergotamine; however, in those cases, patients also received drugs known to be associated with cardiac valvular fibrosis.</paragraph>
                        <paragraph>Administration of ATZUMI should not exceed the dosing guidelines and should not be used for chronic daily administration <content styleCode="italics">[see <linkHtml href="#S2.1">Dosage and Administration (2.1)</linkHtml>]</content>.</paragraph>
                     </text>
                     <effectiveTime value="20250401"/>
                  </section>
               </component>
               <component>
                  <section ID="S5.9">
                     <id root="07c06e54-355b-4e72-b6fb-1278a24c4aae"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>5.9  Local Irritation</title>
                     <text>
                        <paragraph>Local irritative symptoms were reported in 29% of patients treated with at least one dose of ATZUMI in an open-labeled trial, which allowed repeated use of ATZUMI up to 12 months. The common local irritative symptoms (at least 1% of patients) were nasal discomfort (11%), altered taste (8%), nasal congestion (5%), nasopharyngitis (5%), rhinorrhea (4%), cough (3%),  nasal pain (3%), epistaxis (2%), sneezing (2%), nasal pruritus (1%), and increased lacrimation (1%).  If a severe local irritation event occurs for no other attributable reasons, avoid further use of ATZUMI until the event resolves. Monitor patients for severe recurrent local irritation.</paragraph>
                        <paragraph>Nasal tissue in animals treated with dihydroergotamine mesylate daily showed mild mucosal irritation characterized by mucous cell and transitional cell hyperplasia and squamous cell metaplasia. Changes in rat nasal mucosa at 64 weeks were less severe than at 13 weeks. Local effects on respiratory tissue after chronic intranasal dosing in animals have not been evaluated.</paragraph>
                     </text>
                     <effectiveTime value="20250401"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="S6">
               <id root="037dfbd3-1663-46fe-86cd-8daa2aa2a0b1"/>
               <code code="34084-4" codeSystem="2.16.840.1.113883.6.1" displayName="ADVERSE REACTIONS SECTION"/>
               <title>6 ADVERSE REACTIONS</title>
               <text>
                  <paragraph>The following clinically significant adverse reactions are described elsewhere in the labeling:</paragraph>
                  <list listType="unordered" styleCode="disc">
                     <item>Peripheral Ischemia Following Coadministration with Strong CYP3A4 Inhibitors <content styleCode="italics">[see <linkHtml href="#BOX">Boxed Warning</linkHtml> and <linkHtml href="#S5.1">Warnings and Precautions (5.1)</linkHtml>]</content>
                     </item>
                     <item>Myocardial Ischemia and/or Infarction, Other Adverse Cardiac Events, and Fatalities <content styleCode="italics">[see <linkHtml href="#S5.2">Warnings and Precautions (5.2)</linkHtml>]</content>
                     </item>
                     <item>Cerebrovascular Adverse Reactions and Fatalities <content styleCode="italics">[see <linkHtml href="#S5.3">Warnings and Precautions (5.3)</linkHtml>]</content>
                     </item>
                     <item>Other Vasospasm Related Adverse Reactions <content styleCode="italics">[see <linkHtml href="#S5.4">Warnings and Precautions (5.4)</linkHtml>]</content>
                     </item>
                     <item>Increase in Blood Pressure <content styleCode="italics">[see <linkHtml href="#S5.5">Warnings and Precautions (5.5)</linkHtml>]</content>
                     </item>
                     <item>Medication Overuse Headache <content styleCode="italics">[see <linkHtml href="#S5.6">Warnings and Precautions (5.6)</linkHtml>]</content>
                     </item>
                     <item>Preterm Labor <content styleCode="italics">[see <linkHtml href="#S5.7">Warnings and Precautions (5.7)</linkHtml>]</content>
                     </item>
                     <item>Fibrotic Complications <content styleCode="italics">[see <linkHtml href="#S5.8">Warnings and Precautions (5.8)</linkHtml>]</content>
                     </item>
                     <item>Local Irritation <content styleCode="italics">[see <linkHtml href="#S5.9">Warnings and Precautions (5.9)</linkHtml>]</content>
                     </item>
                  </list>
               </text>
               <effectiveTime value="20250401"/>
               <excerpt>
                  <highlight>
                     <text>
                        <paragraph>Most common adverse reactions (incidence &gt; 1%) were rhinitis, nausea, altered sense of taste, application site reactions, dizziness, vomiting, somnolence, pharyngitis, and diarrhea. (<linkHtml href="#S6.1">6.1</linkHtml>)</paragraph>
                        <br/>
                        <paragraph styleCode="bold">To report SUSPECTED ADVERSE REACTIONS, contact Satsuma Pharmaceuticals, Inc. at toll-free phone # 1-888-273-2480 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.</paragraph>
                     </text>
                  </highlight>
               </excerpt>
               <component>
                  <section ID="S6.1">
                     <id root="ca6720a7-8805-46a5-ae70-bc2e8bd6b35e"/>
                     <code code="90374-0" codeSystem="2.16.840.1.113883.6.1" displayName="CLINICAL TRIALS EXPERIENCE SECTION"/>
                     <title>6.1 Clinical Trials Experience</title>
                     <text>
                        <paragraph>Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice.</paragraph>
                        <paragraph>The studies described below were conducted with dihydroergotamine mesylate nasal spray; adverse reactions with ATZUMI nasal powder are expected to be similar to adverse reactions with dihydroergotamine mesylate nasal spray.</paragraph>
                     </text>
                     <effectiveTime value="20250401"/>
                     <component>
                        <section>
                           <id root="333c18fb-6949-43c2-87ab-322f51acdac2"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>
                                 <content styleCode="underline">Adverse Reactions in Placebo-Controlled Trials with Dihydroergotamine Mesylate Nasal Spray <content styleCode="italics">[see <linkHtml href="#S14">Clinical Studies (14)</linkHtml>]</content>
                                 </content>
                              </paragraph>
                              <paragraph>Of the 1,796 patients and subjects treated with dihydroergotamine mesylate nasal spray doses 2 mg or less in U.S. and foreign clinical studies, 26 (1.4%) discontinued because of adverse events. The adverse events associated with discontinuation were, in decreasing order of frequency: rhinitis (13), dizziness (2), facial edema (2), and one patient each due to cold sweats, accidental trauma, depression, elective surgery, somnolence, allergy, vomiting, hypotension, and paraesthesia.  </paragraph>
                              <paragraph>Table 1 summarizes the incidence rates of adverse reactions reported by at least 1% of patients who received dihydroergotamine mesylate nasal spray for the treatment of migraine during placebo-controlled, double-blind clinical studies and were more frequent than in those patients receiving placebo. The most commonly reported adverse reactions (greater than 1% of patients who received dihydroergotamine mesylate nasal spray) were rhinitis, nausea, altered sense of taste, application site reactions, dizziness, vomiting, somnolence, pharyngitis, and diarrhea. In most instances these events were transient and self-limited and did not result in patient discontinuation from a study. </paragraph>
                              <table width="85%">
                                 <caption>Table 1 Adverse Reactions Reported by at Least 1% of the Dihydroergotamine Mesylate Nasal Spray Treated Patients and Occurred more Frequently than in the Placebo-Group in the Migraine Placebo-Controlled Trials </caption>
                                 <col width="40%" align="left" valign="middle"/>
                                 <col width="30%" align="center" valign="middle"/>
                                 <col width="30%" align="center" valign="middle"/>
                                 <thead>
                                    <tr>
                                       <th styleCode="Lrule Rrule"/>
                                       <th styleCode="Rrule">Dihydroergotamine Mesylate Nasal Spray <br/> N=597 <br/> %</th>
                                       <th styleCode="Rrule" valign="top">Placebo <br/> N=631 <br/> %</th>
                                    </tr>
                                 </thead>
                                 <tbody>
                                    <tr styleCode="botrule">
                                       <td styleCode="Lrule Rrule" colspan="3">
                                          <content styleCode="bold">Respiratory System</content>
                                       </td>
                                    </tr>
                                    <tr styleCode="botrule">
                                       <td styleCode="Lrule Rrule">   Rhinitis</td>
                                       <td styleCode="Rrule">26</td>
                                       <td styleCode="Rrule">7</td>
                                    </tr>
                                    <tr styleCode="botrule">
                                       <td styleCode="Lrule Rrule">   Pharyngitis</td>
                                       <td styleCode="Rrule">3</td>
                                       <td styleCode="Rrule">1</td>
                                    </tr>
                                    <tr styleCode="botrule">
                                       <td styleCode="Lrule Rrule" colspan="3">
                                          <content styleCode="bold">Gastrointestinal System</content>
                                       </td>
                                    </tr>
                                    <tr styleCode="botrule">
                                       <td styleCode="Lrule Rrule">   Nausea</td>
                                       <td styleCode="Rrule">10</td>
                                       <td styleCode="Rrule">4</td>
                                    </tr>
                                    <tr styleCode="botrule">
                                       <td styleCode="Lrule Rrule">   Vomiting</td>
                                       <td styleCode="Rrule">4</td>
                                       <td styleCode="Rrule">1</td>
                                    </tr>
                                    <tr styleCode="botrule">
                                       <td styleCode="Lrule Rrule">   Diarrhea</td>
                                       <td styleCode="Rrule">2</td>
                                       <td styleCode="Rrule">&lt;1</td>
                                    </tr>
                                    <tr styleCode="botrule">
                                       <td styleCode="Lrule Rrule" colspan="3">
                                          <content styleCode="bold">Special Senses, Other</content>
                                       </td>
                                    </tr>
                                    <tr styleCode="botrule">
                                       <td styleCode="Lrule Rrule">   Altered Sense of Taste</td>
                                       <td styleCode="Rrule">8</td>
                                       <td styleCode="Rrule">1</td>
                                    </tr>
                                    <tr styleCode="botrule">
                                       <td styleCode="Lrule Rrule" colspan="3">
                                          <content styleCode="bold">Application Site</content>
                                       </td>
                                    </tr>
                                    <tr styleCode="botrule">
                                       <td styleCode="Lrule Rrule">   Application Site Reaction</td>
                                       <td styleCode="Rrule">6</td>
                                       <td styleCode="Rrule">2</td>
                                    </tr>
                                    <tr styleCode="botrule">
                                       <td styleCode="Lrule Rrule" colspan="3">
                                          <content styleCode="bold">Central and Peripheral Nervous System</content>
                                       </td>
                                    </tr>
                                    <tr styleCode="botrule">
                                       <td styleCode="Lrule Rrule">   Dizziness</td>
                                       <td styleCode="Rrule">4</td>
                                       <td styleCode="Rrule">2</td>
                                    </tr>
                                    <tr styleCode="botrule">
                                       <td styleCode="Lrule Rrule">   Somnolence</td>
                                       <td styleCode="Rrule">3</td>
                                       <td styleCode="Rrule">2</td>
                                    </tr>
                                    <tr styleCode="botrule">
                                       <td styleCode="Lrule Rrule" colspan="3">
                                          <content styleCode="bold">Body as a Whole, General</content>
                                       </td>
                                    </tr>
                                    <tr styleCode="botrule">
                                       <td styleCode="Lrule Rrule">   Hot Flashes</td>
                                       <td styleCode="Rrule">1</td>
                                       <td styleCode="Rrule">&lt;1</td>
                                    </tr>
                                    <tr styleCode="botrule">
                                       <td styleCode="Lrule Rrule">   Asthenia</td>
                                       <td styleCode="Rrule">1</td>
                                       <td styleCode="Rrule">0</td>
                                    </tr>
                                    <tr styleCode="botrule">
                                       <td styleCode="Lrule Rrule" colspan="3">
                                          <content styleCode="bold">Musculoskeletal System</content>
                                       </td>
                                    </tr>
                                    <tr>
                                       <td styleCode="Lrule Rrule">   Stiffness</td>
                                       <td styleCode="Rrule">1</td>
                                       <td styleCode="Rrule">&lt;1</td>
                                    </tr>
                                 </tbody>
                              </table>
                           </text>
                           <effectiveTime value="20250401"/>
                        </section>
                     </component>
                     <component>
                        <section>
                           <id root="d2bb7565-68d9-42f0-a3a6-995499bae295"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>
                                 <content styleCode="underline">Adverse Reactions in Studies with ATZUMI</content>
                              </paragraph>
                              <paragraph>An open-label study in adults was conducted to evaluate the safety and tolerability of ATZUMI, with repeated use of ATZUMI over the course of 6 to 12 months.  A total of 344 patients with migraine received at least one dose of ATZUMI. One hundred and eighty-eight patients treated on average at least two migraines per month for at least 6 months, and 86 patients treated at least two migraines per month for at least one year. Of the patients who received at least one dose of ATZUMI, 99 (29%) experienced local irritative symptoms.  Of these, the most common local irritative symptoms (at least 5% of patients) were nasal discomfort, altered taste, nasal congestion, and nasopharyngitis <content styleCode="italics">[see <linkHtml href="#S5.9">Warnings and Precautions (5.9)</linkHtml>]</content>.  The most common adverse reaction resulting in discontinuation in the long-term safety study was nasal discomfort (1.5%).  </paragraph>
                           </text>
                           <effectiveTime value="20250401"/>
                        </section>
                     </component>
                  </section>
               </component>
               <component>
                  <section ID="S6.2">
                     <id root="ea06e78c-1bf5-4c79-94c2-1e152d8726e4"/>
                     <code code="90375-7" codeSystem="2.16.840.1.113883.6.1" displayName="POSTMARKETING EXPERIENCE SECTION"/>
                     <title>6.2 Postmarketing Experience</title>
                     <text>
                        <paragraph>The following adverse reactions have been identified during postapproval use of dihydroergotamine. Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure:</paragraph>
                        <list listType="unordered">
                           <item>
                              <caption> </caption> Vasospasm, paresthesia, hypertension, dizziness, anxiety, dyspnea, headache, flushing, diarrhea, rash, increased sweating, and pleural and retroperitoneal fibrosis after long-term use of dihydroergotamine. Cases of myocardial infarction and stroke have been reported following the use of dihydroergotamine <content styleCode="italics">[see <linkHtml href="#S5.2">Warnings and Precautions (5.2)</linkHtml>]</content>.</item>
                        </list>
                     </text>
                     <effectiveTime value="20250401"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="S7">
               <id root="dd2d0593-4add-4739-8555-aaa5854ce3d3"/>
               <code code="34073-7" codeSystem="2.16.840.1.113883.6.1" displayName="DRUG INTERACTIONS SECTION"/>
               <title>7 DRUG INTERACTIONS</title>
               <effectiveTime value="20250401"/>
               <excerpt>
                  <highlight>
                     <text>
                        <list listType="unordered" styleCode="disc">
                           <item>Beta Blockers/Nicotine: May potentiate/provoke vasoconstriction. (<linkHtml href="#S7.3">7.3</linkHtml>, <linkHtml href="#S7.5">7.5</linkHtml>)</item>
                           <item>Selective Serotonin Reuptake Inhibitors: Weakness, hyperreflexia, and incoordination may occur with coadministration. (<linkHtml href="#S7.6">7.6</linkHtml>)</item>
                        </list>
                     </text>
                  </highlight>
               </excerpt>
               <component>
                  <section ID="S7.1">
                     <id root="4ae114c2-90be-4863-bf62-079c6780438c"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>7.1 CYP3A4 Inhibitors</title>
                     <text>
                        <paragraph>There have been rare reports of serious adverse events in connection with the coadministration of intravenous administration of dihydroergotamine and strong CYP3A4 inhibitors, resulting in vasospasm that led to cerebral ischemia and/or ischemia of the extremities <content styleCode="italics">[see <linkHtml href="#S5.1">Warnings and Precautions (5.1)</linkHtml>].</content> The use of strong CYP3A4 inhibitors with ATZUMI is contraindicated <content styleCode="italics">[see <linkHtml href="#S4">Contraindications (4)</linkHtml>].</content> Administer moderate CYP3A4 inhibitors with caution.</paragraph>
                     </text>
                     <effectiveTime value="20250401"/>
                  </section>
               </component>
               <component>
                  <section ID="S7.2">
                     <id root="6e0f3fe3-6747-43fc-b29a-d0de5522219b"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>7.2 Triptans</title>
                     <text>
                        <paragraph>Triptans (serotonin [5-HT] 1B/1D receptor agonists) have been reported to cause coronary artery vasospasm, and its effects could be additive with ATZUMI. Therefore, triptans and ATZUMI should not be taken within 24 hours of each other <content styleCode="italics">[see <linkHtml href="#S4">Contraindications (4)</linkHtml>]</content>.</paragraph>
                     </text>
                     <effectiveTime value="20250401"/>
                  </section>
               </component>
               <component>
                  <section ID="S7.3">
                     <id root="850b829e-8268-43e1-8776-5d54c72b2928"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>7.3 Beta Blockers</title>
                     <text>
                        <paragraph>There have been reports that propranolol may potentiate the vasoconstrictive action of ergotamine by blocking the vasodilating property of epinephrine.</paragraph>
                     </text>
                     <effectiveTime value="20250401"/>
                  </section>
               </component>
               <component>
                  <section ID="S7.4">
                     <id root="dc212827-622f-4d4a-9183-ad0e0b4df32e"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>7.4 Vasoconstrictors</title>
                     <text>
                        <paragraph>ATZUMI is contraindicated for use with peripheral and central vasoconstrictors because the combination may cause synergistic elevation of blood pressure <content styleCode="italics">[see <linkHtml href="#S5.5">Warnings and Precautions (5.5)</linkHtml>]</content>.</paragraph>
                     </text>
                     <effectiveTime value="20250401"/>
                  </section>
               </component>
               <component>
                  <section ID="S7.5">
                     <id root="15e60645-daee-41d5-98ea-633aaa07905a"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>7.5 Nicotine</title>
                     <text>
                        <paragraph>Nicotine may provoke vasoconstriction in some patients, predisposing to a greater ischemic response to ergot therapy <content styleCode="italics">[see <linkHtml href="#S5.2">Warnings and Precautions (5.2</linkHtml>, <linkHtml href="#S5.4">5.4)</linkHtml>]</content>.</paragraph>
                     </text>
                     <effectiveTime value="20250401"/>
                  </section>
               </component>
               <component>
                  <section ID="S7.6">
                     <id root="e4aed80c-618a-4a5f-9b85-fc47e47975f3"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>7.6 Selective Serotonin Reuptake Inhibitors</title>
                     <text>
                        <paragraph>Weakness, hyperreflexia, and incoordination have been reported rarely when 5-HT<sub>1</sub> agonists have been co-administered with selective serotonin reuptake inhibitors (e.g., fluoxetine, fluvoxamine, paroxetine, sertraline).</paragraph>
                     </text>
                     <effectiveTime value="20250401"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="S8">
               <id root="7414556a-5332-4781-bd14-5148ea924a1c"/>
               <code code="43684-0" codeSystem="2.16.840.1.113883.6.1" displayName="USE IN SPECIFIC POPULATIONS SECTION"/>
               <title>8 USE IN SPECIFIC POPULATIONS</title>
               <effectiveTime value="20250401"/>
               <excerpt>
                  <highlight>
                     <text>
                        <list listType="unordered" styleCode="disc">
                           <item>Pregnancy: Based on animal data, may cause fetal harm. (<linkHtml href="#S8.1">8.1</linkHtml>)</item>
                           <item>Lactation: Advise not to use during breastfeeding. (<linkHtml href="#S8.2">8.2</linkHtml>)</item>
                        </list>
                     </text>
                  </highlight>
               </excerpt>
               <component>
                  <section ID="S8.1">
                     <id root="3ef24bb5-84d7-4b3b-832e-1c3c0a0b9209"/>
                     <code code="42228-7" codeSystem="2.16.840.1.113883.6.1" displayName="PREGNANCY SECTION"/>
                     <title>8.1 Pregnancy</title>
                     <effectiveTime value="20250401"/>
                     <component>
                        <section>
                           <id root="07a2ab93-9d37-4e18-93b7-c43c86b9d33d"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>
                                 <content styleCode="underline">Risk Summary</content>
                              </paragraph>
                              <paragraph>Available data from published literature indicate an increased risk of preterm delivery with dihydroergotamine, the active moiety in ATZUMI, use during pregnancy. Avoid use of ATZUMI during pregnancy <content styleCode="italics">[see <linkHtml href="#S5.7">Warnings and Precautions (5.7)</linkHtml>]</content>. Data collected over decades have shown no increased risk of major birth defects or miscarriage with the use of dihydroergotamine during pregnancy.</paragraph>
                              <paragraph>In animal reproduction studies, adverse effects on development were observed following intranasal administration of dihydroergotamine mesylate during pregnancy (decreased fetal body weight and/or skeletal ossification) in rats and rabbits or during pregnancy and lactation in rats (decreased body weight and impaired reproductive function in the offspring) at doses that were not associated with maternal toxicity <content styleCode="italics">(see <linkHtml href="#Data">Data</linkHtml>)</content>.</paragraph>
                              <paragraph>All pregnancies have a background risk of birth defect, loss, or other adverse outcomes. In the U.S. general population, the estimated background risk of major birth defects and miscarriages in clinically recognized pregnancies is 2% to 4% and 15% to 20%, respectively.  The estimated rate of major birth defects (2.2% to 2.9%) and miscarriage (17%) among deliveries to women with migraine are similar to rates reported in women without migraine.</paragraph>
                           </text>
                           <effectiveTime value="20250401"/>
                        </section>
                     </component>
                     <component>
                        <section>
                           <id root="9abcd4a2-558b-42c6-8c3b-a876359890ce"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>
                                 <content styleCode="underline">Clinical Considerations</content>
                              </paragraph>
                           </text>
                           <effectiveTime value="20250401"/>
                           <component>
                              <section>
                                 <id root="0e853ede-8125-4f92-a7c3-47351bf6b21b"/>
                                 <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                                 <text>
                                    <paragraph>
                                       <content styleCode="italics">Disease-Associated Maternal and/or Embryo/Fetal Risk</content>
                                    </paragraph>
                                    <paragraph>Published data have suggested that women with migraine may be at increased risk of preeclampsia and gestational hypertension during pregnancy.</paragraph>
                                 </text>
                                 <effectiveTime value="20250401"/>
                              </section>
                           </component>
                        </section>
                     </component>
                     <component>
                        <section ID="Data">
                           <id root="db18688f-7d99-42d4-9ccf-2ce852435127"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>
                                 <content styleCode="underline">Data</content>
                              </paragraph>
                           </text>
                           <effectiveTime value="20250401"/>
                           <component>
                              <section>
                                 <id root="4c46c83f-6ca6-4e38-9a88-cb1e04744d93"/>
                                 <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                                 <text>
                                    <paragraph>
                                       <content styleCode="italics">Animal Data </content>
                                    </paragraph>
                                    <paragraph>Intranasal administration of dihydroergotamine mesylate to pregnant rats throughout the period of organogenesis resulted in decreased fetal body weight and/or skeletal ossification at doses of 0.16 mg/day and greater. A no-effect level for adverse effects on embryofetal development was not identified in rats. </paragraph>
                                    <paragraph>Intranasal administration of dihydroergotamine mesylate to pregnant rabbits throughout organogenesis resulted in decreased skeletal ossification at 3.6 mg/day. The no-effect dose for adverse effects on embryofetal development in rabbits was 1.2 mg/day.  </paragraph>
                                    <paragraph>Intranasal administration of dihydroergotamine mesylate to female rats throughout pregnancy and lactation resulted in decreased body weight and impaired reproductive function (decreased mating indices) in the offspring at doses of 0.16 mg/day or greater. A no-effect dose for adverse effects on pre- and postnatal development in rats was not established. Effects on offspring development occurred at doses below those that produced evidence of significant maternal toxicity in these studies. </paragraph>
                                    <paragraph>Dihydroergotamine-induced intrauterine growth retardation has been attributed to reduced uteroplacental blood flow resulting from prolonged vasoconstriction of the uterine vessels and/or increased myometrial tone. </paragraph>
                                 </text>
                                 <effectiveTime value="20250401"/>
                              </section>
                           </component>
                        </section>
                     </component>
                  </section>
               </component>
               <component>
                  <section ID="S8.2">
                     <id root="6ffcd3ad-5564-4071-a05e-6601eb750cf9"/>
                     <code code="77290-5" codeSystem="2.16.840.1.113883.6.1" displayName="LACTATION SECTION"/>
                     <title>8.2 Lactation</title>
                     <effectiveTime value="20250401"/>
                     <component>
                        <section>
                           <id root="a15273f2-e98f-4c36-aa9f-8ebbb2daf100"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>
                                 <content styleCode="underline">Risk Summary</content>
                              </paragraph>
                              <paragraph>There are no data on the presence of dihydroergotamine in human milk; however, ergotamine, a related drug, is present in human milk. There are reports of diarrhea, vomiting, weak pulse, and unstable blood pressure in breastfed infants exposed to ergotamine. ATZUMI may reduce milk supply because it may decrease prolactin levels. Because of the potential for reduced milk supply and serious adverse events in the breastfed infant, including diarrhea, vomiting, weak pulse, and unstable blood pressure, advise patients not to breastfeed during treatment with ATZUMI and for 3 days after the last dose. Breast milk supply during this time should be pumped and discarded.</paragraph>
                           </text>
                           <effectiveTime value="20250401"/>
                        </section>
                     </component>
                  </section>
               </component>
               <component>
                  <section ID="S8.4">
                     <id root="7c089a7a-dacd-4f56-b67b-4db51f62fea4"/>
                     <code code="34081-0" codeSystem="2.16.840.1.113883.6.1" displayName="PEDIATRIC USE SECTION"/>
                     <title>8.4 Pediatric Use</title>
                     <text>
                        <paragraph>The safety and effectiveness of ATZUMI have not been established in pediatric patients.</paragraph>
                     </text>
                     <effectiveTime value="20250401"/>
                  </section>
               </component>
               <component>
                  <section ID="S8.5">
                     <id root="d7ca08ab-1928-4d0b-9103-95b55ddb3039"/>
                     <code code="34082-8" codeSystem="2.16.840.1.113883.6.1" displayName="GERIATRIC USE SECTION"/>
                     <title>8.5 Geriatric Use</title>
                     <text>
                        <paragraph>Clinical studies of ATZUMI and other dihydroergotamine products did not include sufficient numbers of subjects aged 65 and older to determine whether they respond differently from younger subjects. In general, dose selection for an elderly patient should be cautious, usually starting at the low end of the dosing range, reflecting the greater frequency of decreased hepatic, renal, or cardiac function and of concomitant disease or other drug therapy.</paragraph>
                     </text>
                     <effectiveTime value="20250401"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="S9">
               <id root="379a5fe2-ec4c-43cf-ae0b-de06667e87d3"/>
               <code code="42227-9" codeSystem="2.16.840.1.113883.6.1" displayName="DRUG ABUSE AND DEPENDENCE SECTION"/>
               <title>9 DRUG ABUSE AND DEPENDENCE</title>
               <effectiveTime value="20250401"/>
               <component>
                  <section ID="S9.1">
                     <id root="257c5e4a-53e5-4099-8450-17b14f1d8b68"/>
                     <code code="34085-1" codeSystem="2.16.840.1.113883.6.1" displayName="CONTROLLED SUBSTANCE SECTION"/>
                     <title>9.1 Controlled Substance</title>
                     <text>
                        <paragraph>ATZUMI contains dihydroergotamine (as the mesylate salt), which is not a controlled substance.</paragraph>
                     </text>
                     <effectiveTime value="20250401"/>
                  </section>
               </component>
               <component>
                  <section ID="S9.2">
                     <id root="d7d10f9a-c70a-4ee3-bee1-bbdca44e5d94"/>
                     <code code="34086-9" codeSystem="2.16.840.1.113883.6.1" displayName="ABUSE SECTION"/>
                     <title>9.2 Abuse</title>
                     <text>
                        <paragraph>Abuse is the intentional, non-therapeutic use of a drug, even once, for its desirable psychological or physiological effects. Currently available data have not demonstrated drug abuse with dihydroergotamine. However, cases of drug abuse in patients on other forms of ergot therapy have been reported.</paragraph>
                     </text>
                     <effectiveTime value="20250401"/>
                  </section>
               </component>
               <component>
                  <section ID="S9.3">
                     <id root="e2c9a866-16c2-4e62-812e-7cc7f975acca"/>
                     <code code="34087-7" codeSystem="2.16.840.1.113883.6.1" displayName="DEPENDENCE SECTION"/>
                     <title>9.3 Dependence</title>
                     <text>
                        <paragraph>Physical dependence is a state that develops as a result of physiological adaptation in response to repeated drug use, manifested by withdrawal signs and symptoms after abrupt discontinuation or a significant dose reduction of a drug. Currently available data have not demonstrated physical or psychological dependence with dihydroergotamine. However, cases of psychological dependence in patients on other forms of ergot therapy have been reported.</paragraph>
                     </text>
                     <effectiveTime value="20250401"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="S10">
               <id root="4eb25c04-403a-4237-bcf9-15863953ec86"/>
               <code code="34088-5" codeSystem="2.16.840.1.113883.6.1" displayName="OVERDOSAGE SECTION"/>
               <title>10 OVERDOSAGE</title>
               <effectiveTime value="20250401"/>
               <component>
                  <section ID="S10.1">
                     <id root="189759a1-49ac-49bc-84b8-6d14a5b2a933"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>10.1 Symptoms</title>
                     <text>
                        <paragraph>Excessive doses of dihydroergotamine may result in peripheral signs and symptoms of ergotism. In general, the symptoms of an acute ATZUMI overdose may be similar to those of an ergotamine overdose, although there may be less pronounced nausea and vomiting with ATZUMI. The symptoms of an ergotamine overdose include the following: numbness, tingling, pain, and cyanosis of the extremities associated with diminished or absent peripheral pulses; respiratory depression; an increase and/or decrease in blood pressure, usually in that order; confusion, delirium, convulsions, and coma; and/or some degree of nausea, vomiting, and abdominal pain.</paragraph>
                        <paragraph>In laboratory animals, dihydroergotamine mesylate was lethal when given at intravenous doses of 44 mg/kg in mice, 130 mg/kg in rats, and 37 mg/kg in rabbits.</paragraph>
                     </text>
                     <effectiveTime value="20250401"/>
                  </section>
               </component>
               <component>
                  <section ID="S10.2">
                     <id root="dd74272b-8a85-4499-ba34-28db4777e1c4"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>10.2 Treatment</title>
                     <text>
                        <paragraph>Treatment of an overdose of ATZUMI should consist of discontinuation of the drug, general supportive measures including monitoring of vital signs, and observation of the clinical status of the patient for at least 24 hours, or while symptoms or signs persist. Consider contacting the Poison Help line (1-800-222-1222) or a medical toxicologist for additional overdose management recommendations.</paragraph>
                     </text>
                     <effectiveTime value="20250401"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="S11">
               <id root="94fb4ce8-9b4c-4482-b1f5-b1fb02a8a5b7"/>
               <code code="34089-3" codeSystem="2.16.840.1.113883.6.1" displayName="DESCRIPTION SECTION"/>
               <title>11 DESCRIPTION</title>
               <text>
                  <paragraph>ATZUMI contains dihydroergotamine, an ergotamine derivative, as the mesylate salt. Dihydroergotamine mesylate is a white or almost white crystalline powder. It is slightly soluble in water and chloroform and sparingly soluble in methanol. The chemical designation for dihydroergotamine mesylate is (6aR,9R,10aR)-N-[(2R,5S,10aS,10bS)-5-benzyl-10b-hydroxy-2-methyl-3,6-dioxo-octahydro-8H-oxazolo[3,2-α]pyrrolo[2,1-c]pyrazin-2-yl]-7-methyl- 4,6,6a,7,8,9,10,10a-octahydroindolo[4,3-fg]quinoline-9-carboxamide methanesulphonate. The empirical formula is C<sub>33</sub>H<sub>37</sub>N<sub>5</sub>O<sub>5</sub> ∙ CH<sub>4</sub>O<sub>3</sub>S. The molecular weight is 679.80, and it has the following structure:</paragraph>
                  <paragraph>
                     <renderMultiMedia referencedObject="MM1"/>
                  </paragraph>
                  <paragraph>ATZUMI contains dihydroergotamine 5.2 mg (equivalent to 6.0 mg dihydroergotamine mesylate).</paragraph>
                  <paragraph>ATZUMI nasal powder is a drug-device combination product consisting of a powder prefilled in a single-dose delivery device for nasal administration into one nostril.  ATZUMI does not need to be assembled or primed before use. Inactive ingredients are hypromellose, mannitol, and microcrystalline cellulose.</paragraph>
               </text>
               <effectiveTime value="20250401"/>
               <component>
                  <observationMedia ID="MM1">
                     <text>Chemical Structure</text>
                     <value xsi:type="ED" mediaType="image/jpeg">
                        <reference value="atzumi-01.jpg"/>
                     </value>
                  </observationMedia>
               </component>
            </section>
         </component>
         <component>
            <section ID="S12">
               <id root="974629a1-3b77-45b8-b802-b8ad35fc8f06"/>
               <code code="34090-1" codeSystem="2.16.840.1.113883.6.1" displayName="CLINICAL PHARMACOLOGY SECTION"/>
               <title>12 CLINICAL PHARMACOLOGY</title>
               <effectiveTime value="20250401"/>
               <component>
                  <section ID="S12.1">
                     <id root="2187402d-3f07-4c06-a2a3-f64e133a10d3"/>
                     <code code="43679-0" codeSystem="2.16.840.1.113883.6.1" displayName="MECHANISM OF ACTION SECTION"/>
                     <title>12.1 Mechanism of Action</title>
                     <text>
                        <paragraph>Dihydroergotamine binds with high affinity to 5-HT<sub>1Dα</sub> and 5-HT<sub>1Dβ</sub> receptors.</paragraph>
                        <paragraph>The therapeutic activity of dihydroergotamine in migraine is generally attributed to the agonist effects at 5-HT<sub>1D</sub> receptors.</paragraph>
                     </text>
                     <effectiveTime value="20250401"/>
                  </section>
               </component>
               <component>
                  <section ID="S12.2">
                     <id root="11ba3333-0aac-4f0c-aa01-8a1f8562ddda"/>
                     <code code="43681-6" codeSystem="2.16.840.1.113883.6.1" displayName="PHARMACODYNAMICS SECTION"/>
                     <title>12.2 Pharmacodynamics</title>
                     <text>
                        <paragraph>Significant elevation in blood pressure has been reported in patients treated with dihydroergotamine with and without a history of hypertension <content styleCode="italics">[see <linkHtml href="#S5.5">Warnings and Precautions (5.5)</linkHtml>]</content>.</paragraph>
                        <paragraph>Dihydroergotamine possesses oxytocic properties <content styleCode="italics">[see <linkHtml href="#S5.7">Warnings and Precautions (5.7)</linkHtml>]</content>.</paragraph>
                     </text>
                     <effectiveTime value="20250401"/>
                  </section>
               </component>
               <component>
                  <section ID="S12.3">
                     <id root="66643b48-d120-4372-836b-f839319debfa"/>
                     <code code="43682-4" codeSystem="2.16.840.1.113883.6.1" displayName="PHARMACOKINETICS SECTION"/>
                     <title>12.3 Pharmacokinetics</title>
                     <effectiveTime value="20250401"/>
                     <component>
                        <section>
                           <id root="55adfba1-7bb9-46c5-ac0f-68faa29f8f85"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>
                                 <content styleCode="underline">Absorption</content>
                              </paragraph>
                              <paragraph>Following ATZUMI administration, the mean maximum plasma concentration was 2.1 ng/mL, and the median time from dosing to maximum plasma concentration was approximately 0.5 hours.</paragraph>
                           </text>
                           <effectiveTime value="20250401"/>
                        </section>
                     </component>
                     <component>
                        <section>
                           <id root="0f9462a8-87f7-414a-ad7d-81e36520c6d4"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>
                                 <content styleCode="underline">Distribution</content>
                              </paragraph>
                              <paragraph>Dihydroergotamine is 93% plasma protein bound. The apparent steady-state volume of distribution is approximately 800 liters.</paragraph>
                           </text>
                           <effectiveTime value="20250401"/>
                        </section>
                     </component>
                     <component>
                        <section>
                           <id root="dc3597f9-1c3f-4180-9396-4876ec8d1733"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>
                                 <content styleCode="underline">Elimination</content>
                              </paragraph>
                              <paragraph>The mean apparent half-life of dihydroergotamine following nasal administration of ATZUMI in healthy subjects is approximately 13 hours.</paragraph>
                           </text>
                           <effectiveTime value="20250401"/>
                           <component>
                              <section>
                                 <id root="1fd15abe-95fd-4ba6-9e59-a8e03b255654"/>
                                 <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                                 <text>
                                    <paragraph>
                                       <content styleCode="italics">Metabolism</content>
                                    </paragraph>
                                    <paragraph>Four dihydroergotamine mesylate metabolites have been identified in human plasma following oral administration. The major metabolite, 8'-β-hydroxydihydroergotamine, exhibits affinity equivalent to its parent for adrenergic and 5-HT<sub>1</sub> receptors and demonstrates equivalent potency in several venoconstrictor activity models, in vivo and in vitro. The other metabolites, (i.e., dihydrolysergic acid, dihydrolysergic amide) and a metabolite formed by oxidative opening of the proline ring are of minor importance.</paragraph>
                                    <paragraph>Following nasal administration of ATZUMI, the 8'-β-hydroxydihydroergotamine metabolite plasma AUC was approximately 16% of the plasma AUC of dihydroergotamine, and the mean C<sub>max</sub> (5.7% of parent) was below the minimal concentrations required for receptor binding for adrenergic and 5-HT<sub>1</sub> receptors.</paragraph>
                                 </text>
                                 <effectiveTime value="20250401"/>
                              </section>
                           </component>
                           <component>
                              <section>
                                 <id root="072ea517-8d78-48e8-9327-66b5ad145a42"/>
                                 <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                                 <text>
                                    <paragraph>
                                       <content styleCode="italics">Excretion</content>
                                    </paragraph>
                                    <paragraph>The major excretory route of dihydroergotamine is via the bile in the feces. The total body clearance following ATZUMI administration is 1.5 L/min which reflects mainly hepatic clearance. The renal clearance (0.1 L/min) is unaffected by the route of dihydroergotamine administration based on other dihydroergotamine products.</paragraph>
                                 </text>
                                 <effectiveTime value="20250401"/>
                              </section>
                           </component>
                        </section>
                     </component>
                     <component>
                        <section>
                           <id root="706db9fb-7660-4af6-b4dc-e3d900ff1850"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>
                                 <content styleCode="underline">Specific Populations</content>
                              </paragraph>
                              <paragraph>No studies have been conducted on the effect of renal or hepatic impairment, gender, race, ethnicity, or pregnancy on dihydroergotamine pharmacokinetics <content styleCode="italics">[see <linkHtml href="#S4">Contraindications (4)</linkHtml>, <linkHtml href="#S8.1">Use in Specific Populations (8.1)</linkHtml>]</content>.</paragraph>
                           </text>
                           <effectiveTime value="20250401"/>
                        </section>
                     </component>
                     <component>
                        <section>
                           <id root="cec06e36-0ed2-445b-b010-376591a07e07"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>
                                 <content styleCode="underline">Drug Interaction Studies</content>
                              </paragraph>
                           </text>
                           <effectiveTime value="20250401"/>
                           <component>
                              <section>
                                 <id root="19f2e7e6-7313-4950-930a-2b6cb77efdb1"/>
                                 <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                                 <text>
                                    <paragraph>
                                       <content styleCode="italics">CYP3A4 Inhibitors</content>
                                    </paragraph>
                                    <paragraph>In a drug interaction study, administration of ATZUMI with itraconazole increased dihydroergotamine plasma exposure by 14% for C<sub>max</sub> and 19% for AUC while the plasma exposures (C<sub>max</sub> and AUC<sub>0-inf</sub>) of 8'-β-hydroxy dihydroergotamine (8'-OH-DHE, active metabolite) were increased by approximately 4-fold and 3-fold, respectively <content styleCode="italics">[see <linkHtml href="#S4">Contraindications (4)</linkHtml>, <linkHtml href="#S5.1">Warnings and Precautions (5.1)</linkHtml>, <linkHtml href="#S7.1">Drug Interactions (7.1)</linkHtml>]</content>.</paragraph>
                                 </text>
                                 <effectiveTime value="20250401"/>
                              </section>
                           </component>
                           <component>
                              <section>
                                 <id root="bcb3ba49-7f35-44ac-b8d4-a07dd7a4b87f"/>
                                 <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                                 <text>
                                    <paragraph>
                                       <content styleCode="italics">Other Drugs</content>
                                    </paragraph>
                                    <paragraph>The pharmacokinetics of dihydroergotamine did not appear to be significantly affected by the concomitant use of a local vasoconstrictor.</paragraph>
                                    <paragraph>Multiple oral doses of the β-adrenoceptor antagonist propranolol, used for preventive treatment of migraine, had no significant influence on the C<sub>max</sub>, T<sub>max</sub> or AUC of dihydroergotamine doses up to 4 mg <content styleCode="italics">[see <linkHtml href="#S7.3">Drug Interactions (7.3)</linkHtml>].</content>
                                    </paragraph>
                                    <paragraph>The effect of oral contraceptives on the pharmacokinetics of dihydroergotamine has not been studied.</paragraph>
                                 </text>
                                 <effectiveTime value="20250401"/>
                              </section>
                           </component>
                        </section>
                     </component>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="S13">
               <id root="14c1053c-c381-4a6a-a577-4768a64367e6"/>
               <code code="43680-8" codeSystem="2.16.840.1.113883.6.1" displayName="NONCLINICAL TOXICOLOGY SECTION"/>
               <title>13 NONCLINICAL TOXICOLOGY</title>
               <effectiveTime value="20250401"/>
               <component>
                  <section ID="S13.1">
                     <id root="aba982fa-c9e1-470f-9e0e-8b76f678dc2b"/>
                     <code code="34083-6" codeSystem="2.16.840.1.113883.6.1" displayName="CARCINOGENESIS &amp; MUTAGENESIS &amp; IMPAIRMENT OF FERTILITY SECTION"/>
                     <title>13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility</title>
                     <effectiveTime value="20250401"/>
                     <component>
                        <section>
                           <id root="8c6c4587-c7a7-49c5-a9d0-de3bd3880857"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>
                                 <content styleCode="underline">Carcinogenesis</content>
                              </paragraph>
                              <paragraph>In a 2-year mouse carcinogenicity study, subcutaneous administration of dihydroergotamine mesylate (0, 0.5, 1.5, or 5 mg/kg/day) resulted in an increased incidence of fibrosarcoma at the injection sites in males and females at the high dose.   </paragraph>
                              <paragraph>In a 2-year rat carcinogenicity study, intranasal administration of dihydroergotamine mesylate (0, 0.4, 0.8, or 1.6 mg/day for 13 weeks, followed by 0, 0.08, 0.24, or 0.8 mg/day for the remainder of the study) did not result in an increase in tumors.</paragraph>
                           </text>
                           <effectiveTime value="20250401"/>
                        </section>
                     </component>
                     <component>
                        <section>
                           <id root="739f59ce-429c-4a3b-b7b8-3bef12d766c3"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>
                                 <content styleCode="underline">Mutagenesis</content>
                              </paragraph>
                              <paragraph>Dihydroergotamine mesylate was negative in an in vitro mutagenicity (Ames) assay and positive in in vitro chromosomal aberration (V79 Chinese hamster cell assay with metabolic activation, and human peripheral blood lymphocyte) assays. Dihydroergotamine was negative in in vivo micronucleus assays in mouse and hamster.</paragraph>
                           </text>
                           <effectiveTime value="20250401"/>
                        </section>
                     </component>
                     <component>
                        <section>
                           <id root="be1fc250-1339-4b0c-9b52-6b7088fc4840"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>
                                 <content styleCode="underline">Impairment of Fertility </content>
                              </paragraph>
                              <paragraph>Intranasal administration of dihydroergotamine to rats at doses up to 1.6 mg/day was not associated with adverse effects on fertility.</paragraph>
                           </text>
                           <effectiveTime value="20250401"/>
                        </section>
                     </component>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="S14">
               <id root="5cba4ab4-b9eb-4df2-8d7b-bfe6b203dfe0"/>
               <code code="34092-7" codeSystem="2.16.840.1.113883.6.1" displayName="CLINICAL STUDIES SECTION"/>
               <title>14 CLINICAL STUDIES</title>
               <text>
                  <paragraph>The efficacy of ATZUMI for the acute treatment of migraine with or without aura in adults was based on the relative bioavailability of ATZUMI nasal powder compared to dihydroergotamine mesylate nasal spray<content styleCode="italics">.</content>
                  </paragraph>
                  <paragraph>The clinical trials described below were conducted using dihydroergotamine mesylate nasal spray.</paragraph>
                  <paragraph>The efficacy of dihydroergotamine mesylate nasal spray for the acute treatment of migraine headaches was evaluated in four randomized, double-blind, placebo controlled studies in the U.S. The patient population for the trials was predominantly female (87%) and Caucasian (95%) with a mean age of 39 years (range 18 to 65 years). Patients treated a single moderate to severe migraine headache with a single dose of study medication and assessed pain severity over the 24 hours following treatment. Headache response was determined 0.5, 1, 2, 3 and 4 hours after dosing and was defined as a reduction in headache severity to mild or no pain. In studies 1 and 2, a four-point pain intensity scale was utilized; in studies 3 and 4, a five-point scale was used to record pain response. Although rescue medication was allowed in all four studies, patients were instructed not to use them during the four hour observation period. In studies 3 and 4, a total dose of 2 mg was compared to placebo. In studies 1 and 2, doses of 2 and 3 mg were evaluated, and showed no advantage of the higher dose for a single treatment. In all studies, patients received a regimen consisting of 0.5 mg in each nostril, repeated in 15 minutes (and again in another 15 minutes for the 3 mg dose in studies 1 and 2). </paragraph>
                  <paragraph>The percentage of patients achieving headache response 4 hours after treatment was significantly greater in patients receiving 2 mg doses of dihydroergotamine mesylate nasal spray compared to those receiving placebo in 3 of the 4 studies (see <linkHtml href="#table2">Table 2</linkHtml> and <linkHtml href="#table3">Table 3</linkHtml> and <linkHtml href="#fig1">Figure 1</linkHtml> and <linkHtml href="#fig2">Figure 2</linkHtml>). </paragraph>
                  <table width="85%" ID="table2">
                     <caption>Table 2 Studies 1 and 2: Percentage of Patients with Headache Response<footnote>Headache response was defined as a reduction in headache severity to mild or no pain. Headache response was based on pain intensity as interpreted by the patient using a four-point pain intensity scale.</footnote> 2 and 4 Hours Following a Single Treatment of Study Medication (Dihydroergotamine Mesylate Nasal Spray or Placebo)</caption>
                     <col width="10%" align="left" valign="middle"/>
                     <col width="30%" align="left" valign="middle"/>
                     <col width="20%" align="center" valign="middle"/>
                     <col width="20%" align="center" valign="middle"/>
                     <col width="20%" align="center" valign="middle"/>
                     <thead>
                        <tr>
                           <th styleCode="Lrule Rrule"/>
                           <th styleCode="Rrule"/>
                           <th styleCode="Rrule" valign="bottom">N</th>
                           <th styleCode="Rrule" valign="bottom">2 hours</th>
                           <th styleCode="Rrule" valign="bottom">4 hours</th>
                        </tr>
                     </thead>
                     <tbody>
                        <tr styleCode="botrule">
                           <td styleCode="Lrule Rrule" rowspan="2">
                              <content styleCode="bold">Study 1</content>
                           </td>
                           <td styleCode="Rrule">Dihydroergotamine mesylate nasal spray</td>
                           <td styleCode="Rrule">105</td>
                           <td styleCode="Rrule">61%<footnote ID="fnote">p value &lt; 0.001</footnote>
                           </td>
                           <td styleCode="Rrule">70%<footnoteRef IDREF="fnote"/>
                           </td>
                        </tr>
                        <tr styleCode="botrule">
                           <td styleCode="Rrule">Placebo</td>
                           <td styleCode="Rrule" align="center">98</td>
                           <td styleCode="Rrule">23%</td>
                           <td styleCode="Rrule">28%</td>
                        </tr>
                        <tr styleCode="botrule">
                           <td styleCode="Lrule Rrule"/>
                           <td styleCode="Rrule">Difference from Placebo</td>
                           <td styleCode="Rrule"/>
                           <td styleCode="Rrule">37%</td>
                           <td styleCode="Rrule">42%</td>
                        </tr>
                        <tr styleCode="botrule">
                           <td styleCode="Lrule Rrule" rowspan="2">
                              <content styleCode="bold">Study 2</content>
                           </td>
                           <td styleCode="Rrule">Dihydroergotamine mesylate nasal spray</td>
                           <td styleCode="Rrule">103</td>
                           <td styleCode="Rrule">47%</td>
                           <td styleCode="Rrule">56%<footnote>p value &lt; 0.01</footnote>
                           </td>
                        </tr>
                        <tr styleCode="botrule">
                           <td styleCode="Rrule">Placebo</td>
                           <td styleCode="Rrule" align="center">102</td>
                           <td styleCode="Rrule">33%</td>
                           <td styleCode="Rrule">35%</td>
                        </tr>
                        <tr>
                           <td styleCode="Lrule Rrule"/>
                           <td styleCode="Rrule">Difference from Placebo</td>
                           <td styleCode="Rrule"/>
                           <td styleCode="Rrule">14%</td>
                           <td styleCode="Rrule">21%</td>
                        </tr>
                     </tbody>
                  </table>
                  <table width="85%" ID="table3">
                     <caption>Table 3 Studies 3 and 4: Percentage of Patients with Headache Response<footnote>Headache response was defined as a reduction in headache severity to mild or no pain. Headache response was evaluated on a five-point scale that included pain response.</footnote> 2 and 4 Hours Following a Single Treatment of Study Medication (Dihydroergotamine Mesylate Nasal Spray or Placebo) </caption>
                     <col width="10%" align="left" valign="middle"/>
                     <col width="30%" align="left" valign="middle"/>
                     <col width="20%" align="center" valign="middle"/>
                     <col width="20%" align="center" valign="middle"/>
                     <col width="20%" align="center" valign="middle"/>
                     <thead>
                        <tr>
                           <th styleCode="Lrule Rrule"/>
                           <th styleCode="Rrule"/>
                           <th styleCode="Rrule" valign="bottom">N</th>
                           <th styleCode="Rrule" valign="bottom">2 hours</th>
                           <th styleCode="Rrule" valign="bottom">4 hours</th>
                        </tr>
                     </thead>
                     <tbody>
                        <tr styleCode="botrule">
                           <td styleCode="Lrule Rrule" rowspan="2" valign="top">
                              <content styleCode="bold">Study 3</content>
                           </td>
                           <td styleCode="Rrule">Dihydroergotamine mesylate nasal spray</td>
                           <td styleCode="Rrule">50</td>
                           <td styleCode="Rrule">32%</td>
                           <td styleCode="Rrule">48%<footnote>p value &lt; 0.01</footnote>
                           </td>
                        </tr>
                        <tr styleCode="botrule">
                           <td styleCode="Rrule">Placebo</td>
                           <td styleCode="Rrule" align="center">50</td>
                           <td styleCode="Rrule">20%</td>
                           <td styleCode="Rrule">22%</td>
                        </tr>
                        <tr styleCode="botrule">
                           <td styleCode="Lrule Rrule"/>
                           <td styleCode="Rrule">Difference from Placebo</td>
                           <td styleCode="Rrule"/>
                           <td styleCode="Rrule">12%</td>
                           <td styleCode="Rrule">26%</td>
                        </tr>
                        <tr styleCode="botrule">
                           <td styleCode="Lrule Rrule" rowspan="2" valign="top">
                              <content styleCode="bold">Study 4</content>
                           </td>
                           <td styleCode="Rrule">Dihydroergotamine mesylate nasal spray</td>
                           <td styleCode="Rrule">47</td>
                           <td styleCode="Rrule">30%</td>
                           <td styleCode="Rrule">47%</td>
                        </tr>
                        <tr styleCode="botrule">
                           <td styleCode="Rrule">Placebo</td>
                           <td styleCode="Rrule" align="center">50</td>
                           <td styleCode="Rrule">20%</td>
                           <td styleCode="Rrule">30%</td>
                        </tr>
                        <tr>
                           <td styleCode="Lrule Rrule"/>
                           <td styleCode="Rrule">Difference from Placebo</td>
                           <td styleCode="Rrule"/>
                           <td styleCode="Rrule">10%</td>
                           <td styleCode="Rrule">17%</td>
                        </tr>
                     </tbody>
                  </table>
                  <paragraph>The Kaplan-Meier plots below (Figure 1 and Figure 2) provides an estimate of the probability that a patient will have responded to a single 2 mg dose of dihydroergotamine mesylate nasal spray as a function of the time elapsed since initiation of treatment. </paragraph>
                  <table width="85%" ID="fig1" styleCode="Noautorules">
                     <caption>Figure 1 Estimated Probability of a Patient Responding During the Four Hours Following a Single 2 mg Dose of Dihydroergotamine Mesylate Nasal Spray as a Function of the Time Elapsed Since Initiation of Treatment<footnote>The figure shows the probability over time of obtaining a response following treatment with dihydroergotamine mesylate nasal spray. Headache response was based on pain intensity as interpreted by the patient using a four-point pain intensity scale. Patients not achieving response within 4 hours were censored to 4 hours.</footnote>
                     </caption>
                     <col width="100%" align="center" valign="middle"/>
                     <tbody>
                        <tr>
                           <td>
                              <renderMultiMedia referencedObject="MM2"/>
                           </td>
                        </tr>
                     </tbody>
                  </table>
                  <table width="85%" ID="fig2" styleCode="Noautorules">
                     <caption>Figure 2 Estimated Probability of a Patient Responding to Dihydroergotamine Mesylate Nasal Spray During the Four Hours Following Dosing<footnote>The figure shows the probability over time of obtaining a response following treatment with dihydroergotamine mesylate nasal spray. Headache response was evaluated on a five-point scale that included pain response. Patients not achieving response within 4 hours were censored to 4 hours.</footnote>
                     </caption>
                     <col width="100%" align="center" valign="middle"/>
                     <tbody>
                        <tr>
                           <td>
                              <renderMultiMedia referencedObject="MM3"/>
                           </td>
                        </tr>
                     </tbody>
                  </table>
                  <paragraph>For patients with migraine-associated nausea, photophobia, and phonophobia at baseline, there was a lower incidence of these symptoms at 2 and 4 hours following administration of dihydroergotamine mesylate nasal spray compared to placebo.</paragraph>
                  <paragraph>Patients were not allowed to use additional treatments for 8 hours prior to study medication dosing and during the 4-hour observation period following study treatment. Following the 4-hour observation period, patients were allowed to use additional treatments. For all studies, the estimated probability of patients using additional treatments for their migraines over the 24 hours following the single 2 mg dose of study treatment is summarized in Figure 3 below.</paragraph>
                  <table width="85%" ID="fig3" styleCode="Noautorules">
                     <caption>Figure 3 Estimated Probability of a Patient Using Additional Treatments for Migraine Over the 24 Hours Following Either Dihydroergotamine Mesylate Nasal Spray 2 mg (or Placebo)<footnote>Kaplan-Meier plot based on data obtained from all studies with patients not using additional treatments censored to 24 hours. All patients received a single treatment of study medication for their migraine attack. The plot also includes patients who had no response to the initial dose.</footnote>
                     </caption>
                     <col width="100%" align="center" valign="middle"/>
                     <tbody>
                        <tr>
                           <td>
                              <renderMultiMedia referencedObject="MM4"/>
                           </td>
                        </tr>
                     </tbody>
                  </table>
                  <paragraph>Neither age nor sex appear to affect the patient's response to dihydroergotamine mesylate nasal spray. The racial distribution of patients was insufficient to determine the effect of race on the efficacy of dihydroergotamine mesylate nasal spray.</paragraph>
               </text>
               <effectiveTime value="20250401"/>
               <component>
                  <observationMedia ID="MM2">
                     <text>Figure</text>
                     <value xsi:type="ED" mediaType="image/jpeg">
                        <reference value="atzumi-02.jpg"/>
                     </value>
                  </observationMedia>
               </component>
               <component>
                  <observationMedia ID="MM3">
                     <text>Figure</text>
                     <value xsi:type="ED" mediaType="image/jpeg">
                        <reference value="atzumi-03.jpg"/>
                     </value>
                  </observationMedia>
               </component>
               <component>
                  <observationMedia ID="MM4">
                     <text>Figure</text>
                     <value xsi:type="ED" mediaType="image/jpeg">
                        <reference value="atzumi-04.jpg"/>
                     </value>
                  </observationMedia>
               </component>
            </section>
         </component>
         <component>
            <section ID="S16">
               <id root="5f903e4c-7236-40a3-a37e-c0f83abbd445"/>
               <code code="34069-5" codeSystem="2.16.840.1.113883.6.1" displayName="HOW SUPPLIED SECTION"/>
               <title>16 HOW SUPPLIED/STORAGE AND HANDLING</title>
               <effectiveTime value="20250401"/>
               <component>
                  <section>
                     <id root="847c1d1c-9ff3-4a9e-9b40-d7d2d9b713ba"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>16.1 How Supplied</title>
                     <text>
                        <paragraph>ATZUMI (dihydroergotamine) nasal powder is supplied in a single-dose nasal device with white powder containing 5.2 mg of dihydroergotamine. ATZUMI is available in a carton of 8 nasal devices each individually packaged in a protective foil pouch (NDC 76978-101-08).</paragraph>
                     </text>
                     <effectiveTime value="20250401"/>
                  </section>
               </component>
               <component>
                  <section>
                     <id root="450625cf-016f-4737-8f9a-13fcab89240b"/>
                     <code code="44425-7" codeSystem="2.16.840.1.113883.6.1" displayName="STORAGE AND HANDLING SECTION"/>
                     <title>16.2 Storage and Handling</title>
                     <text>
                        <paragraph>Store ATZUMI at controlled room temperature, 20°C to 25°C (68°F to 77°F), with excursions allowed between 15°C to 30°C (59°F to 86°F).</paragraph>
                        <paragraph>Store ATZUMI in its protective foil pouch until ready to use.</paragraph>
                     </text>
                     <effectiveTime value="20250401"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="S17">
               <id root="e0746454-3904-4d6e-b6ed-6bc570492ff2"/>
               <code code="34076-0" codeSystem="2.16.840.1.113883.6.1" displayName="INFORMATION FOR PATIENTS SECTION"/>
               <title>17 PATIENT COUNSELING INFORMATION</title>
               <text>
                  <paragraph>Advise the patient to read the FDA-approved patient labeling (Medication Guide and Instructions for Use).</paragraph>
               </text>
               <effectiveTime value="20250401"/>
               <component>
                  <section>
                     <id root="0b0f9e3f-12f1-4edc-b2b2-8150dc1bda5e"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <text>
                        <paragraph>
                           <content styleCode="underline">Serious and/or Life-Threatening Reactions with Coadministration of CYP3A4 Inhibitors</content>
                        </paragraph>
                        <paragraph>Inform patients that serious and/or life-threatening peripheral ischemia (cerebral ischemia and/or ischemia of the extremities) has been associated with the coadministration of dihydroergotamine and strong CYP3A4 inhibitors, such as macrolide antibiotics and protease inhibitors <content styleCode="italics">[see <linkHtml href="#S4">Contraindications (4)</linkHtml>, <linkHtml href="#S5.1">Warnings and Precautions (5.1)</linkHtml>, <linkHtml href="#S7.1">and Drug Interactions (7.1)</linkHtml>].</content>
                        </paragraph>
                     </text>
                     <effectiveTime value="20250401"/>
                  </section>
               </component>
               <component>
                  <section>
                     <id root="7251b79f-914c-423d-912e-6fbc8b0c882c"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <text>
                        <paragraph>
                           <content styleCode="underline">Myocardial Ischemia and/or Infarction, Other Cardiac Events, Cerebrovascular Events, and Fatalities</content>
                        </paragraph>
                        <paragraph>Inform patients of the risk for serious cardiac, cerebrovascular, and other vasospasm related events. Advise patients to notify their healthcare provider if they develop any risk factors or symptoms while taking ATZUMI. Inform patients that nicotine may provoke vasoconstriction predisposing to a greater ischemic response <content styleCode="italics">[see <linkHtml href="#S5.2">Warnings and Precautions (5.2</linkHtml>, <linkHtml href="#S5.3">5.3</linkHtml>, <linkHtml href="#S5.4">5.4)</linkHtml>]</content>.</paragraph>
                     </text>
                     <effectiveTime value="20250401"/>
                  </section>
               </component>
               <component>
                  <section>
                     <id root="47039c6a-4fe3-4528-baf5-ae41847718e4"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <text>
                        <paragraph>
                           <content styleCode="underline">Increase in Blood Pressure</content>
                        </paragraph>
                        <paragraph>Inform patients of the risk for significant elevation in blood pressure <content styleCode="italics">[see <linkHtml href="#S5.5">Warnings and Precautions (5.5)</linkHtml>]</content>.</paragraph>
                     </text>
                     <effectiveTime value="20250401"/>
                  </section>
               </component>
               <component>
                  <section>
                     <id root="61d8307e-9db3-4da7-882b-42fabf19c2f6"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <text>
                        <paragraph>
                           <content styleCode="underline">Medication Overuse Headache</content>
                        </paragraph>
                        <paragraph>Inform patients that use of drugs to treat migraine attacks for 10 or more days per month may lead to an exacerbation of headache, and encourage patients to record headache frequency and drug use (e.g., by keeping a headache diary) <content styleCode="italics">[see <linkHtml href="#S5.6">Warnings and Precautions (5.6)</linkHtml>].</content>
                        </paragraph>
                     </text>
                     <effectiveTime value="20250401"/>
                  </section>
               </component>
               <component>
                  <section>
                     <id root="f3058394-71a2-4fbe-8efb-87f13fcdbaab"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <text>
                        <paragraph>
                           <content styleCode="underline">Local Irritation</content>
                        </paragraph>
                        <paragraph>Advise patients to notify their healthcare provider if they have bothersome local irritation <content styleCode="italics">[see <linkHtml href="#S5.9">Warning and Precautions (5.9)</linkHtml>].</content>
                        </paragraph>
                     </text>
                     <effectiveTime value="20250401"/>
                  </section>
               </component>
               <component>
                  <section>
                     <id root="fe7afef8-4bee-4f3c-97ad-7b0e684ba82f"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <text>
                        <paragraph>
                           <content styleCode="underline">Drug Interactions</content>
                        </paragraph>
                        <paragraph>Advise patients to inform their healthcare providers if they are taking, or plan to take, any prescription or over-the-counter drugs, since there is a potential for interactions <content styleCode="italics">[see <linkHtml href="#S7">Drug Interactions (7)</linkHtml>]</content>.</paragraph>
                     </text>
                     <effectiveTime value="20250401"/>
                  </section>
               </component>
               <component>
                  <section>
                     <id root="76b3975c-16d8-4384-b127-5be8617ea6ab"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <text>
                        <paragraph>
                           <content styleCode="underline">Pregnancy</content>
                        </paragraph>
                        <paragraph>Advise patients of the risk for preterm birth. Advise women to inform their healthcare provider if they are pregnant or intend to become pregnant <content styleCode="italics">[see <linkHtml href="#S5.7">Warnings and Precautions (5.7)</linkHtml>, <linkHtml href="#S8.1">Use in Specific Populations (8.1)</linkHtml>]</content>.</paragraph>
                     </text>
                     <effectiveTime value="20250401"/>
                  </section>
               </component>
               <component>
                  <section>
                     <id root="a96ea6d5-3262-4fee-add4-0329b7065796"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <text>
                        <paragraph>
                           <content styleCode="underline">Lactation</content>
                        </paragraph>
                        <paragraph>Advise patients not to breastfeed during treatment with ATZUMI <content styleCode="italics">[see <linkHtml href="#S8.2">Use In Specific Populations (8.2)</linkHtml>]</content>.</paragraph>
                     </text>
                     <effectiveTime value="20250401"/>
                  </section>
               </component>
               <component>
                  <section>
                     <id root="4f858eb0-5c11-4ef6-97ef-5214a826a3e9"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <text>
                        <paragraph>
                           <content styleCode="underline">Administration Instructions</content>
                        </paragraph>
                        <paragraph>Instruct patients not to squeeze ATZUMI before inserting it into the nostril because priming is not required. Inform patients that they will need to squeeze the air pump on the ATZUMI device three separate times into one nostril to give a dose. Instruct the patient to squeeze while inhaling, release to allow the air pump to expand back to its original shape, then repeat two more times <content styleCode="italics">[see <linkHtml href="#IFU">Instructions for Use</linkHtml>].</content> Tell patients to use fast, complete, pulse-like squeezes to deliver their dose. <content styleCode="italics">[see <linkHtml href="#S2.3">Dosage and Administration (2.3)</linkHtml>].</content>
                        </paragraph>
                     </text>
                     <effectiveTime value="20250401"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section>
               <id root="6a3009a7-ef34-4db8-b4f2-8bad2e6b0d51"/>
               <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
               <text>
                  <paragraph>Manufactured for Satsuma Pharmaceuticals, Inc., 4819 Emperor Blvd., Suite 340, Durham, NC 27703</paragraph>
                  <paragraph>© 2025. Satsuma Pharmaceuticals, Inc. All rights reserved. <br/> ATZUMI is a trademark of Satsuma Pharmaceuticals, Inc.</paragraph>
               </text>
               <effectiveTime value="20250401"/>
            </section>
         </component>
         <component>
            <section>
               <id root="5aa54cd3-24c6-4d19-9b8e-75aa8605e355"/>
               <code code="42231-1" codeSystem="2.16.840.1.113883.6.1" displayName="SPL MEDGUIDE SECTION"/>
               <text>
                  <table width="100%">
                     <col width="5%" align="left" valign="middle"/>
                     <col width="20%" align="left" valign="middle"/>
                     <col width="30%" align="left" valign="middle"/>
                     <col width="45%" align="left" valign="middle"/>
                     <thead>
                        <tr>
                           <th styleCode="Lrule Rrule" colspan="4" align="center">MEDICATION GUIDE <br/> ATZUMI™ (at zoo' mee) <br/> (dihydroergotamine) <br/> nasal powder</th>
                        </tr>
                     </thead>
                     <tfoot>
                        <tr>
                           <td colspan="3">This Medication Guide has been approved by the U.S. Food and Drug Administration.</td>
                           <td align="right">Issued: 04/2025</td>
                        </tr>
                     </tfoot>
                     <tbody>
                        <tr>
                           <td styleCode="Lrule Rrule" colspan="4">
                              <content styleCode="bold" ID="mostimportantinformation">What is the most important information I should know about ATZUMI? <br/> ATZUMI can cause serious side effects, including:</content>
                              <list listType="unordered" styleCode="disc">
                                 <item>
                                    <content styleCode="bold">Serious problems with blood circulation to your legs and feet (peripheral ischemia).</content> ATZUMI can cause peripheral ischemia when you take it with certain medicines known as CYP3A4 inhibitors. Peripheral ischemia may lead to a stroke and death. Stop taking ATZUMI and get emergency medical help right away if you have any of the following symptoms: 										<list listType="unordered" styleCode="circle">
                                       <item>cramping and pain in your legs or hips</item>
                                       <item>feeling of heaviness or tightness in your leg muscles</item>
                                       <item>burning or aching pain in your feet or toes while resting</item>
                                       <item>numbness, tingling, or weakness in your legs</item>
                                       <item>cold feeling or color changes in 1 or both legs or feet</item>
                                       <item>slurred speech</item>
                                       <item>sudden weakness</item>
                                    </list>
                                 </item>
                              </list>									Do not take medicines known as strong CYP3A4 inhibitors, such as:</td>
                        </tr>
                        <tr>
                           <td styleCode="Lrule"/>
                           <td>
                              <list listType="unordered" styleCode="circle">
                                 <item>ritonavir</item>
                                 <item>nelfinavir</item>
                              </list>
                           </td>
                           <td>
                              <list listType="unordered" styleCode="circle">
                                 <item>erythromycin</item>
                                 <item>clarithromycin</item>
                              </list>
                           </td>
                           <td styleCode="Rrule">
                              <list listType="unordered" styleCode="circle">
                                 <item>ketoconazole</item>
                                 <item>itraconazole</item>
                              </list>
                           </td>
                        </tr>
                        <tr styleCode="botrule">
                           <td styleCode="Lrule Rrule" colspan="4">These are not all of the medicines that could affect how ATZUMI works. Your healthcare provider can tell you if it is safe to take ATZUMI with other medicines. </td>
                        </tr>
                        <tr styleCode="botrule">
                           <td styleCode="Lrule Rrule" colspan="4">
                              <content styleCode="bold">What is ATZUMI?</content>
                              <br/> ATZUMI is a prescription medicine used for the acute treatment of migraine with or without aura in adults. 									<list listType="unordered" styleCode="disc">
                                 <item>ATZUMI is not used to prevent migraine.</item>
                                 <item>ATZUMI is not used to treat other types of headaches such as hemiplegic (that make you unable to move on one side of your body) or basilar (rare form of migraine with aura) migraines.</item>
                              </list>									It is not known if ATZUMI is safe and effective in children.</td>
                        </tr>
                        <tr styleCode="botrule">
                           <td styleCode="Lrule Rrule" colspan="4">
                              <content styleCode="bold">Who should not take ATZUMI? <br/> Do not take ATZUMI if you: </content>
                              <list listType="unordered" styleCode="disc">
                                 <item>are taking medicines known as strong CYP3A4 inhibitors.</item>
                                 <item>have heart problems or a history of heart problems.</item>
                                 <item>have uncontrolled high blood pressure.</item>
                                 <item>have narrowing of blood vessels in your legs, arms, stomach, or kidneys (peripheral vascular disease).</item>
                                 <item>have sepsis.</item>
                                 <item>have had vascular surgery.</item>
                                 <item>have severe liver problems.</item>
                                 <item>have severe kidney problems.</item>
                                 <item>are allergic to dihydroergotamine, ergot alkaloids, or any of the ingredients in ATZUMI.  See the end of this Medication Guide for a complete list of ingredients in ATZUMI.</item>
                                 <item>have taken any of the following medicines in the last 24 hours: <list listType="unordered" styleCode="circle">
                                       <item>sumatriptan</item>
                                       <item>almotriptan</item>
                                       <item>eletriptan</item>
                                       <item>frovatriptan</item>
                                       <item>naratriptan</item>
                                       <item>rizatriptan</item>
                                       <item>zolmitriptan</item>
                                       <item>ergotamine or ergotamine-type medicines</item>
                                    </list>
                                 </item>
                                 <item>have taken any medicines that constrict your blood vessels or raise your blood pressure.</item>
                              </list>									Ask your healthcare provider if you are not sure if you are taking any of these medicines. <br/> Your healthcare provider can tell you if it is safe to take ATZUMI with other medicines.</td>
                        </tr>
                        <tr styleCode="botrule">
                           <td styleCode="Lrule Rrule" colspan="4">
                              <content styleCode="bold" ID="beforeyoutake">Before you take ATZUMI, tell your healthcare provider about all of your medical conditions, including if you:</content>
                              <list listType="unordered" styleCode="disc">
                                 <item>have high blood pressure.</item>
                                 <item>have liver problems.</item>
                                 <item>have kidney problems.</item>
                                 <item>have risk factors for heart disease. You have a higher risk for heart disease if you: 										<list listType="unordered" styleCode="circle">
                                       <item>have high blood pressure</item>
                                       <item>have high cholesterol levels</item>
                                       <item>smoke</item>
                                       <item>are overweight</item>
                                       <item>have diabetes</item>
                                       <item>have a family history of heart disease</item>
                                    </list>
                                 </item>
                                 <item>are taking medicines known as strong CYP3A4 inhibitors.</item>
                                 <item>are pregnant or plan to become pregnant.  ATZUMI may cause preterm labor.  ATZUMI should be avoided during pregnancy. Talk to your healthcare provider right away if you are pregnant or want to become pregnant.</item>
                                 <item>are breastfeeding or plan to breastfeed. ATZUMI may reduce breast milk supply and pass into your breast milk. ATZUMI may be harmful to your baby. Do not breastfeed your baby while taking ATZUMI and for 3 days after you use ATZUMI. Talk with your healthcare provider about the best way to feed your baby if you take ATZUMI.</item>
                              </list>
                              <content styleCode="bold">Tell your healthcare provider about all the medicines you take,</content> including prescription and over-the-counter medicines, vitamins, and herbal supplements. Your healthcare provider will decide if you can take ATZUMI with your other medicines. </td>
                        </tr>
                        <tr styleCode="botrule">
                           <td styleCode="Lrule Rrule" colspan="4">
                              <content styleCode="bold">How should I take ATZUMI?</content>
                              <list listType="unordered" styleCode="disc">
                                 <item>ATZUMI is for nasal use only (use in the nose).</item>
                                 <item>Certain people should take their first dose of ATZUMI in their healthcare provider's office or in another medical setting. Ask your healthcare provider if you should take your first dose in a medical setting.</item>
                                 <item>Use ATZUMI exactly as your healthcare provider tells you to use it. Read and follow the instructions in the Instructions for Use or use the Quick Reference Guide located on the ATZUMI protective foil pouch.</item>
                                 <item>If your headache comes back after the first complete dose or you only get some relief from your headache, you can use a second dose 1 hour after the first complete dose. Use a new ATZUMI nasal powder device for the second dose, if needed.</item>
                                 <item>Do not take more than 2 doses of ATZUMI within a 24-hour period. It is not known if it is safe to take more than 4 doses of ATZUMI in a 7-day period or 12 doses in a 30-day period.</item>
                                 <item>Taking ATZUMI for 10 or more days in 1 month may make your headaches worse. You should write down when you have headaches and when you take ATZUMI so that you can talk with your healthcare provider about how ATZUMI is working for you. See "<linkHtml href="#whatarethepossible">What are the possible side effects of ATZUMI?</linkHtml>".</item>
                              </list>									If you use too much ATZUMI, call your healthcare provider or Poison Help line at 1-800-222-1222, or go to the nearest hospital emergency room right away.</td>
                        </tr>
                        <tr>
                           <td styleCode="Lrule Rrule" colspan="4">
                              <content styleCode="bold" ID="whatarethepossible">What are the possible side effects of ATZUMI? <br/> ATZUMI can cause serious side effects, including:</content>
                              <br/> See <content styleCode="bold">"<linkHtml href="#mostimportantinformation">What is the most important information I should know about ATZUMI?</linkHtml>"</content>
                              <list listType="unordered" styleCode="disc">
                                 <item>
                                    <content styleCode="bold">Heart attack and other heart problems.</content> Heart problems may lead to death. Stop taking ATZUMI and get emergency medical help right away if you have any of the following symptoms of a heart attack: 										<list listType="unordered" styleCode="circle">
                                       <item>discomfort in the center of your chest that lasts for more than a few minutes, or that goes away and comes back</item>
                                       <item>severe tightness, pain, pressure, or heaviness in your chest, throat, neck, or jaw</item>
                                       <item>pain or discomfort in your arms, back, neck, jaw, or stomach</item>
                                       <item>shortness of breath with or without chest discomfort</item>
                                       <item>breaking out in a cold sweat</item>
                                       <item>feeling lightheaded</item>
                                       <item>nausea or vomiting</item>
                                    </list>
                                 </item>
                              </list>
                           </td>
                        </tr>
                        <tr>
                           <td styleCode="Lrule"/>
                           <td styleCode="Rrule" colspan="3">ATZUMI is not for people with risk factors for heart disease unless a heart exam is done and shows no problem. See <content styleCode="bold">"<linkHtml href="#beforeyoutake">Before you take ATZUMI, tell your healthcare provider about all of your medical conditions, including if you:</linkHtml>"</content> for the risk factors for heart disease.</td>
                        </tr>
                        <tr>
                           <td styleCode="Lrule Rrule" colspan="4">
                              <list listType="unordered" styleCode="disc">
                                 <item>
                                    <content styleCode="bold">Stroke.</content> Stop taking ATZUMI and get emergency medical help right away if you have any of the following symptoms of a stroke: <list listType="unordered" styleCode="circle">
                                       <item>face drooping</item>
                                       <item>unusual weakness or numbness</item>
                                       <item>slurred speech</item>
                                    </list>
                                 </item>
                                 <item>
                                    <content styleCode="bold">Changes in color or sensation in your fingers and toes (Raynaud's syndrome).</content>
                                 </item>
                                 <item>
                                    <content styleCode="bold">Stomach and intestinal problems</content> (gastrointestinal and colonic ischemic events). Symptoms of gastrointestinal and colonic ischemic events include<content styleCode="bold">:</content>
                                    <list listType="unordered" styleCode="circle">
                                       <item>sudden or severe stomach pain</item>
                                       <item>constipation or diarrhea</item>
                                       <item>stomach pain after meals</item>
                                       <item>bloody diarrhea</item>
                                       <item>weight loss</item>
                                       <item>fever</item>
                                       <item>nausea or vomiting</item>
                                    </list>
                                 </item>
                                 <item>
                                    <content styleCode="bold">Increased blood pressure.</content>
                                 </item>
                                 <item>
                                    <content styleCode="bold">Medicine overuse headache.</content> Some people who use too much ATZUMI may make their headaches worse (medicine overuse headache). If your headaches get worse, your healthcare provider may decide to stop your treatment with ATZUMI.</item>
                                 <item>
                                    <content styleCode="bold">Preterm labor.</content>
                                 </item>
                                 <item>
                                    <content styleCode="bold">Tissue changes (fibrotic complications).</content> Inflammation and fiber-like tissue that is not normal (fibrosis) can occur around the lungs and stomach.</item>
                                 <item>
                                    <content styleCode="bold">Nose irritation.</content> Discomfort in your nose, change in taste, stuffy nose, and cold-type symptoms, (such as, runny nose, sneezing, and cough) can occur.</item>
                              </list>
                              <content styleCode="bold">The most common side effects of ATZUMI include</content>:</td>
                        </tr>
                        <tr>
                           <td styleCode="Lrule"/>
                           <td>
                              <list listType="unordered" styleCode="disc">
                                 <item>runny nose</item>
                                 <item>nausea</item>
                                 <item>abnormal taste</item>
                              </list>
                           </td>
                           <td>
                              <list listType="unordered" styleCode="disc">
                                 <item>application site reactions</item>
                                 <item>dizziness</item>
                                 <item>vomiting</item>
                              </list>
                           </td>
                           <td styleCode="Rrule">
                              <list listType="unordered" styleCode="disc">
                                 <item>sleepiness</item>
                                 <item>sore throat</item>
                                 <item>diarrhea</item>
                              </list>
                           </td>
                        </tr>
                        <tr styleCode="botrule">
                           <td styleCode="Lrule Rrule" colspan="4">These are not all of the possible side effects of ATZUMI.  <br/> Call your doctor for medical advice about side effects.  You may report side effects to FDA at 1-800-FDA-1088.</td>
                        </tr>
                        <tr styleCode="botrule">
                           <td styleCode="Lrule Rrule" colspan="4">
                              <content styleCode="bold">How should I store ATZUMI?</content>
                              <list listType="unordered" styleCode="disc">
                                 <item>Store ATZUMI at room temperature between 68°F to 77°F (20°C to 25°C).</item>
                                 <item>Store ATZUMI in its protective foil pouch until ready to use.</item>
                              </list>
                              <content styleCode="bold">Keep ATZUMI and all medicines out of the reach of children.</content>
                           </td>
                        </tr>
                        <tr styleCode="botrule">
                           <td styleCode="Lrule Rrule" colspan="4">
                              <content styleCode="bold">General information about the safe and effective use of ATZUMI. </content>
                              <br/> Medicines are sometimes prescribed for purposes other than those listed in a Medication Guide. Do not use ATZUMI for a condition for which it was not prescribed. Do not give ATZUMI to other people, even if they have the same symptoms you have. It may harm them. You can ask your pharmacist or healthcare provider for information about ATZUMI that is written for health professionals.</td>
                        </tr>
                        <tr>
                           <td styleCode="Lrule Rrule" colspan="4">
                              <content styleCode="bold">What are the ingredients in ATZUMI?</content>
                              <br/>
                              <content styleCode="bold">Active ingredient:</content> Dihydroergotamine <br/>
                              <content styleCode="bold">Inactive ingredients:</content> Hypromellose, mannitol, and microcrystalline cellulose <br/> ATZUMI is a trademark of Satsuma Pharmaceuticals, Inc.  <br/> Manufactured for Satsuma Pharmaceuticals, Inc., Durham, NC 27703  <br/> © 2025. Satsuma Pharmaceuticals, Inc. All rights reserved.  <br/> For more information, go to www.atzumi.com or call 1-888-273-2480.</td>
                        </tr>
                     </tbody>
                  </table>
               </text>
               <effectiveTime value="20250401"/>
            </section>
         </component>
         <component>
            <section ID="IFU">
               <id root="21756b57-c23d-49ff-b85d-1b985cea19c2"/>
               <code code="59845-8" codeSystem="2.16.840.1.113883.6.1" displayName="INSTRUCTIONS FOR USE SECTION"/>
               <title>INSTRUCTIONS FOR USE</title>
               <text>
                  <paragraph styleCode="bold">ATZUMI™ (at zoo' mee) <br/> (dihydroergotamine) <br/> nasal powder</paragraph>
                  <paragraph styleCode="bold">For Nasal Use Only</paragraph>
                  <paragraph>This <content styleCode="bold">Instructions for Use</content> contains information on how to use ATZUMI.</paragraph>
                  <paragraph>
                     <content styleCode="bold">Read this Instructions for Use before using ATZUMI.</content>
                  </paragraph>
                  <paragraph>
                     <renderMultiMedia referencedObject="MM5"/>
                  </paragraph>
                  <paragraph>
                     <renderMultiMedia referencedObject="MM6"/>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">Important Information You Need to Know Before Using ATZUMI</content>
                  </paragraph>
                  <list listType="unordered" styleCode="disc">
                     <item>ATZUMI contains 1 complete dose of medicine and should be thrown away after each use.</item>
                     <item>ATZUMI is for nasal (nose) use only.</item>
                     <item>Deliver all the powdered medicine into only 1 nostril.</item>
                     <item>
                        <content styleCode="bold">Do not</content> use ATZUMI if it is damaged or expired.</item>
                     <item>
                        <content styleCode="bold">Do not</content> squeeze ATZUMI before inserting it into the nostril. Priming is not required.</item>
                     <item>Powdered medicine is inside the blue nozzle. When you squeeze the white air pump, air is pushed into the blue nozzle and pushes the powdered medicine into your nose.</item>
                     <item>
                        <content styleCode="bold">Do not</content> squeeze slowly, partially or with any hesitation. When dosing, you must fully squeeze the white air pump as fast as you can. A fast, pulse-like squeezing action is needed.</item>
                  </list>
                  <paragraph>
                     <content styleCode="bold">How often can you use ATZUMI?</content>
                  </paragraph>
                  <list listType="unordered" styleCode="disc">
                     <item>If needed, you may take a second dose 1 hour after your first dose. Wait at least 1 hour before taking the second dose.</item>
                     <item>
                        <content styleCode="bold">Do not</content> take more than 2 doses within a 24-hour period.</item>
                     <item>It is not known if it is safe to take more than 4 doses of ATZUMI in a 7-day period or 12 doses in a 30-day period.</item>
                  </list>
                  <paragraph>
                     <content styleCode="bold">Storing ATZUMI</content>
                  </paragraph>
                  <list listType="unordered" styleCode="disc">
                     <item>Store ATZUMI at room temperature between 68°F to 77°F (20°C to 25°C).</item>
                     <item>Store ATZUMI in its protective foil pouch until ready to use (Figure C).</item>
                     <item>
                        <content styleCode="bold">Keep ATZUMI and all medicines out of the reach of children.</content>
                        <renderMultiMedia referencedObject="MM7"/>
                     </item>
                  </list>
                  <paragraph styleCode="bold">Step 1. Preparing to Use ATZUMI</paragraph>
                  <list listType="unordered">
                     <item>
                        <caption> </caption>
                        <content styleCode="bold">1.1 Blow Your Nose</content>
                        <br/>
                        <renderMultiMedia referencedObject="MM8"/> Blow your nose to clear your nostrils (Figure D).</item>
                     <item>
                        <caption> </caption>
                        <content styleCode="bold">1.2 Take Out ATZUMI</content>
                        <renderMultiMedia referencedObject="MM9"/> Open the protective foil pouch by tearing at the notch. <br/> Remove ATZUMI from the protective foil pouch (Figure E).</item>
                     <item>
                        <caption> </caption>
                        <content styleCode="bold">1.3 Check ATZUMI</content>
                        <renderMultiMedia referencedObject="MM10"/>
                        <content styleCode="bold">Check</content> the <content styleCode="bold">Expiration Date</content> to make sure ATZUMI is not expired (Figure F). <br/>
                        <content styleCode="bold">Check</content> ATZUMI <content styleCode="bold">for damage</content>. <br/> If ATZUMI is expired or damaged, throw it away in your household trash and get a new ATZUMI.</item>
                     <item>
                        <caption> </caption>
                        <content styleCode="bold">1.4 Remove Clear Cap </content>
                        <renderMultiMedia referencedObject="MM11"/> Pull the clear cap straight off (Figure G).</item>
                  </list>
                  <paragraph styleCode="bold">Step 2. Using ATZUMI</paragraph>
                  <list listType="unordered">
                     <item>
                        <caption> </caption>
                        <content styleCode="bold">2.1 Remove Round Blue Tab</content>
                        <renderMultiMedia referencedObject="MM12"/>Hold the nozzle base in 1 hand. <br/> Remove the round blue tab by bending it back and forth or twisting it to break it off (Figure H). <br/> This creates an opening for the powdered medicine to pass through. <br/>
                        <content styleCode="bold">Important: Do not</content> squeeze the white air pump yet. Wait until Step 2.3. </item>
                     <item>
                        <caption> </caption>
                        <content styleCode="bold">2.2 Insert Into Nostril</content>
                        <renderMultiMedia referencedObject="MM13"/> Hold the white air pump as shown in Figure I and insert the blue nozzle into 1 nostril as far as it will comfortably go. The nozzle base should touch your nose (Figure I).</item>
                     <item>
                        <caption> </caption>
                        <content styleCode="bold">2.3 Deliver All of the Powdered Medicine into Only 1 Nostril</content>
                     </item>
                     <item>
                        <caption> </caption> • <content styleCode="bold">Squeeze the white air pump 3 separate times into 1 nostril. Inhale through your nose each time you squeeze</content> (Figure J).</item>
                     <item>
                        <caption> </caption> • <content styleCode="bold">Fast, complete, pulse-like squeezes</content> are needed to push the powdered medicine and deliver the complete dose.</item>
                     <item>
                        <caption> </caption> • <content styleCode="bold">Do not</content> squeeze slowly, partially or with any hesitation.</item>
                     <item>
                        <caption> </caption> • Allow the white air pump to expand back to its original shape between squeezes (Figure J). <renderMultiMedia referencedObject="MM14"/>
                        <content styleCode="bold">Important:</content>
                        <br/> Deliver all the powdered medicine into only 1 nostril. <renderMultiMedia referencedObject="MM15"/>
                     </item>
                  </list>
                  <paragraph styleCode="bold">Step 3. Inspecting ATZUMI</paragraph>
                  <list listType="unordered">
                     <item>
                        <caption> </caption>
                        <content styleCode="bold">3.1 Check for Remaining Powdered Medicine</content>
                        <renderMultiMedia referencedObject="MM16"/>
                     </item>
                     <item>
                        <caption> </caption> • Keep ATZUMI upright and <content styleCode="bold">look inside the blue nozzle</content> to see if any loose powdered medicine remains at the bottom (Figure K).</item>
                     <item>
                        <caption> </caption> • If loose powdered medicine remains, <content styleCode="bold">repeat Step 2.3 to dose into the same nostril, but squeeze the white air pump faster</content>.  Repeat Step 2.3 until no loose powdered medicine remains. <br/>
                        <content styleCode="bold">Note:</content>
                     </item>
                     <item>
                        <caption> </caption> • It is normal to see a light coating of powdered medicine in the blue nozzle after delivering the complete dose.</item>
                     <item>
                        <caption> </caption> • If you are not sure whether you have delivered all of the loose powdered medicine, then repeat Step 2.3 with the same ATZUMI device in the same nostril.</item>
                  </list>
                  <paragraph styleCode="bold">Step 4. Throwing Away ATZUMI</paragraph>
                  <list listType="unordered">
                     <item>
                        <caption> </caption>
                        <renderMultiMedia referencedObject="MM17"/> After use, throw away the protective foil pouch, the ATZUMI device, the round blue tab, and the clear cap in your household trash (Figure L). <br/>
                        <content styleCode="bold">Do not</content> save ATZUMI after use. ATZUMI contains a one-time (single) dose.</item>
                  </list>
                  <paragraph>This Instructions for Use has been approved by the U.S. Food and Drug Administration. <br/>Approved: 4/2025 </paragraph>
                  <paragraph styleCode="bold">Quick Reference Guide</paragraph>
                  <paragraph>This is a Quick Reference Guide. Read the full <content styleCode="bold">Instructions for Use</content> before using ATZUMI. <content styleCode="bold">Deliver ATZUMI into only 1 nostril.</content>
                  </paragraph>
                  <list listType="ordered">
                     <item>
                        <content styleCode="bold">Blow</content> your nose to clear your nostrils.</item>
                     <item>
                        <content styleCode="bold">Pull</content> the clear cap straight off.</item>
                     <item>
                        <content styleCode="bold">Twist</content> or bend the round blue tab to break it off. <renderMultiMedia referencedObject="MM18"/>
                     </item>
                     <item>
                        <content styleCode="bold">Insert</content> the blue nozzle all the way into your nostril. <renderMultiMedia referencedObject="MM19"/>
                     </item>
                     <item>
                        <content styleCode="bold">Squeeze the white air pump 3 separate times into 1 nostril. Inhale through your nose each time you squeeze</content>. Fast, complete, pulse-like squeezes are needed. <content styleCode="bold">Do not</content> squeeze slowly, partially or with hesitation. <br/> Allow the white air pump to expand back to its original shape between squeezes. <br/> Deliver all of the powdered medicine into only 1 nostril. <renderMultiMedia referencedObject="MM20"/>
                     </item>
                     <item>
                        <content styleCode="bold">Check</content> inside the blue nozzle. If loose powdered medicine remains, <content styleCode="bold">repeat Step 5 with the same ATZUMI device in the same nostril, but with a faster squeeze</content>. <renderMultiMedia referencedObject="MM21"/>
                     </item>
                     <item>
                        <content styleCode="bold">Throw away</content> ATZUMI in your household trash. ATZUMI is for one-time (single) use only.</item>
                  </list>
                  <paragraph>This Quick Reference Guide has been approved by the U.S. Food and Drug Administration.<br/> Approved: 04/2025</paragraph>
               </text>
               <effectiveTime value="20250401"/>
               <component>
                  <observationMedia ID="MM5">
                     <text>Image</text>
                     <value xsi:type="ED" mediaType="image/jpeg">
                        <reference value="atzumi-05.jpg"/>
                     </value>
                  </observationMedia>
               </component>
               <component>
                  <observationMedia ID="MM6">
                     <text>Image</text>
                     <value xsi:type="ED" mediaType="image/jpeg">
                        <reference value="atzumi-06.jpg"/>
                     </value>
                  </observationMedia>
               </component>
               <component>
                  <observationMedia ID="MM7">
                     <text>Image</text>
                     <value xsi:type="ED" mediaType="image/jpeg">
                        <reference value="atzumi-07.jpg"/>
                     </value>
                  </observationMedia>
               </component>
               <component>
                  <observationMedia ID="MM8">
                     <text>Image</text>
                     <value xsi:type="ED" mediaType="image/jpeg">
                        <reference value="atzumi-08.jpg"/>
                     </value>
                  </observationMedia>
               </component>
               <component>
                  <observationMedia ID="MM9">
                     <text>Image</text>
                     <value xsi:type="ED" mediaType="image/jpeg">
                        <reference value="atzumi-09.jpg"/>
                     </value>
                  </observationMedia>
               </component>
               <component>
                  <observationMedia ID="MM10">
                     <text>Image</text>
                     <value xsi:type="ED" mediaType="image/jpeg">
                        <reference value="atzumi-10.jpg"/>
                     </value>
                  </observationMedia>
               </component>
               <component>
                  <observationMedia ID="MM11">
                     <text>Image</text>
                     <value xsi:type="ED" mediaType="image/jpeg">
                        <reference value="atzumi-11.jpg"/>
                     </value>
                  </observationMedia>
               </component>
               <component>
                  <observationMedia ID="MM12">
                     <text>Image</text>
                     <value xsi:type="ED" mediaType="image/jpeg">
                        <reference value="atzumi-12.jpg"/>
                     </value>
                  </observationMedia>
               </component>
               <component>
                  <observationMedia ID="MM13">
                     <text>Image</text>
                     <value xsi:type="ED" mediaType="image/jpeg">
                        <reference value="atzumi-13.jpg"/>
                     </value>
                  </observationMedia>
               </component>
               <component>
                  <observationMedia ID="MM14">
                     <text>Image</text>
                     <value xsi:type="ED" mediaType="image/jpeg">
                        <reference value="atzumi-14.jpg"/>
                     </value>
                  </observationMedia>
               </component>
               <component>
                  <observationMedia ID="MM15">
                     <text>Image</text>
                     <value xsi:type="ED" mediaType="image/jpeg">
                        <reference value="atzumi-15.jpg"/>
                     </value>
                  </observationMedia>
               </component>
               <component>
                  <observationMedia ID="MM16">
                     <text>Image</text>
                     <value xsi:type="ED" mediaType="image/jpeg">
                        <reference value="atzumi-16.jpg"/>
                     </value>
                  </observationMedia>
               </component>
               <component>
                  <observationMedia ID="MM17">
                     <text>Image</text>
                     <value xsi:type="ED" mediaType="image/jpeg">
                        <reference value="atzumi-17.jpg"/>
                     </value>
                  </observationMedia>
               </component>
               <component>
                  <observationMedia ID="MM18">
                     <text>Image</text>
                     <value xsi:type="ED" mediaType="image/jpeg">
                        <reference value="atzumi-18.jpg"/>
                     </value>
                  </observationMedia>
               </component>
               <component>
                  <observationMedia ID="MM19">
                     <text>Image</text>
                     <value xsi:type="ED" mediaType="image/jpeg">
                        <reference value="atzumi-19.jpg"/>
                     </value>
                  </observationMedia>
               </component>
               <component>
                  <observationMedia ID="MM20">
                     <text>Image</text>
                     <value xsi:type="ED" mediaType="image/jpeg">
                        <reference value="atzumi-20.jpg"/>
                     </value>
                  </observationMedia>
               </component>
               <component>
                  <observationMedia ID="MM21">
                     <text>Image</text>
                     <value xsi:type="ED" mediaType="image/jpeg">
                        <reference value="atzumi-21.jpg"/>
                     </value>
                  </observationMedia>
               </component>
            </section>
         </component>
         <component>
            <section>
               <id root="c3c41fdf-8414-4316-aeb3-d6df699e5c08"/>
               <code code="51945-4" codeSystem="2.16.840.1.113883.6.1" displayName="PACKAGE LABEL.PRINCIPAL DISPLAY PANEL"/>
               <title>PRINCIPAL DISPLAY PANEL - 5.2 mg Bottle Carton</title>
               <text>
                  <paragraph>Atzumi™ <br/> (dihydroergotamine) <br/> nasal powder</paragraph>
                  <paragraph>5.2 mg</paragraph>
                  <paragraph>For nasal use only. <br/> Discard after use. <br/> Contains:</paragraph>
                  <list listType="unordered" styleCode="disc">
                     <item>8 preﬁlled single-dose devices</item>
                     <item>Instructions for Use</item>
                     <item>Medication Guide</item>
                     <item>Prescribing Information</item>
                  </list>
                  <paragraph>Nasal devices not for individual sale. <br/> Dispense entire carton and accompanying Medication Guide to each patient.</paragraph>
                  <paragraph>Rx Only <br/> NDC 76978-101-08</paragraph>
                  <paragraph>© 2025 Satsuma Pharmaceuticals, Inc. All rights reserved.</paragraph>
                  <renderMultiMedia referencedObject="MM22"/>
               </text>
               <effectiveTime value="20250401"/>
               <component>
                  <observationMedia ID="MM22">
                     <text>PRINCIPAL DISPLAY PANEL - 5.2 mg Bottle Carton</text>
                     <value xsi:type="ED" mediaType="image/jpeg">
                        <reference value="atzumi-22.jpg"/>
                     </value>
                  </observationMedia>
               </component>
            </section>
         </component>
         <component>
            <section>
               <id root="d68a5f15-6a47-4d1c-b916-832e0721a875"/>
               <code code="51945-4" codeSystem="2.16.840.1.113883.6.1" displayName="PACKAGE LABEL.PRINCIPAL DISPLAY PANEL"/>
               <title>PRINCIPAL DISPLAY PANEL - 5.2 mg Device Pouch Label</title>
               <text>
                  <paragraph>Atzumi™ <br/> (dihydroergotamine) <br/> nasal powder</paragraph>
                  <paragraph>5.2 mg</paragraph>
                  <paragraph>For nasal use only. <br/> Discard after use. <br/> Recommended Dosage: See Prescribing <br/> Information. <br/> Contains 1 prefilled single-dose device. <br/> Nasal devices not for individual sale. <br/> Store ATZUMI in its protective pouch at room <br/> temperature 68°F to 77°F (20°C to 25°C). <br/> Excursions allowed between 59°F to 86°F <br/> (15°C to 30°C). </paragraph>
                  <paragraph>Keep out of reach of children. <br/> INSTRUCTIONS <br/> ON REVERSE</paragraph>
                  <paragraph>Rx Only <br/> NDC 76978-101-01</paragraph>
                  <paragraph>Manufactured for <br/> Satsuma Pharmaceuticals, Inc. <br/> Durham, NC 27703 </paragraph>
                  <paragraph>© 2025 Satsuma Pharmaceuticals, Inc. All rights reserved.</paragraph>
                  <renderMultiMedia referencedObject="MM23"/>
               </text>
               <effectiveTime value="20250401"/>
               <component>
                  <observationMedia ID="MM23">
                     <text>PRINCIPAL DISPLAY PANEL - 5.2 mg Device Pouch Label</text>
                     <value xsi:type="ED" mediaType="image/jpeg">
                        <reference value="atzumi-23.jpg"/>
                     </value>
                  </observationMedia>
               </component>
            </section>
         </component>
      </structuredBody>
   </component>
</document>